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ABSTRACT 
Babies bom to diabetic mothers show increased incidence of congenital 
malformations. In particular, caudal regression syndrome is well-documented to be 
highly associated with diabetic pregnancy, but the pathogenic mechanism remains 
unclear. Interestingly, exposure to excess dW-trans retinoic acid (RA), or 
homologous deletion of the RA catabolizing enzyme Cyp26al, a member of the 
cytochrome P450 family, led to caudal regression and other malformations that 
closely phenocopied anomalies found in diabetic pregnancies. Our laboratory has 
recently demonstrated that embryos of diabetic mice showed significantly lower 
level of expression of Cyp26al. The aim of this thesis is to test our hypothesis that 
down-regulation of Cyp26al under maternal diabetes reduces the embryo's ability to 
catabolize RA and increases its effective concentration, thereby increasing the risk 
in developing caudal regression. 
First, I have established an in vitro assay system to compare the ability 
of the caudal region of embryos of diabetic and non-diabetic mice to degrade RA. 
The caudal region was excised and put into medium containing RA at a known 
concentration. After incubation, RA remained in the medium was quantified with a 
highly sensitive RA responsive cell line. Results showed that when supplemented 
with cytochrome P450 enzyme cofactor and reducing agent, the caudal region could 
degrade RA in the medium, but this activity was completely inhibited by co-
treatment with a CYP26 specific inhibitor. Moreover, the quantity of RA remained 
in the medium in the diabetic group was significantly more than that in the non-
diabetic group. These findings support that the caudal region of embryos of diabetic 
mice has reduced ability to catabolize RA via a CYP26 enzyme. 
Next, I have compared the in vivo rate of removal of exogenously 
applied RA by the caudal region of embryos of diabetic and non-diabetic mice. This 
was achieved by administration of RA into pregnant mice. RA remained in the 
caudal region of embryo was measured at hourly intervals using the RA responsive 
cell line. Results showed that at all time points studied, the concentration of RA in 
the diabetic group was significantly higher than that in the non-diabetic group, such 
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that there was a two-fold difference in the area-under-curve (AUCo-g hours) between 
the two groups. These results indicated that following RA treatment, there was 
indeed a higher effective concentration of RA in the caudal region of embryos of 
diabetic mice. 
So far, three Cyp26 genes have been identified: Cyp26al, Cyp26bl and 
Cyp26cl. Using quantitative RT-PCR, I have found that Cyp26al was the 
predominant subtype in the caudal region of the embryo. Significant differences in 
expression levels were detected only for Cyp26al, but not for Cyp26bl and 
Cyp26cl between diabetic and non-diabetic groups. After maternal RA treatment, 
Cyp26al was significantly up-regulated, but to a much lesser extent in embryos of 
diabetic mice. Hence, further indicating that the rate of catabolism of the 
exogenously applied RA would be less in the diabetic group. 
Lastly, I have compared the susceptibility of Cyp26al heterozygous 
embryos and their wild-type littermates developed in diabetic and non-diabetic 
pregnancies to RA-induced caudal regression. It was found that heterozygous 
embryos with haploinsufficiency of Cyp26a 1 developed in maternal diabetes had the 
least ability to catabolize RA and exhibited most severe caudal regression, whereas 
wild-type embryos in non-diabetic pregnancies showed the least susceptibility to 
RA-induced caudal regression. 
Taken together, results of this thesis have provided strong evidence to 
support a direct role of down-regulation of Cyp26a 1 under maternal diabetes in 
increasing the risk of the embryo to develop caudal regression. 







































Chapter 1: General Introduction 
1.1. DIABETES MELLITUS 
Diabetes mellitus is a metabolic disorder characterized by 
hyperglycemia and other symptoms as a result of impaired insulin production and/or 
insulin resistance. Diabetes can cause many complications. If not properly controlled, 
acute complications such as hypoglycemia, ketoacidosis or nonketotic hyperosmolar 
coma may develop. Serious long-term complications include retinal damage, 
diabetic nephropathy and cardiovascular diseases, which could be lethal. 
The prevalence of diagnosed diabetes in adults in the United States has 
risen substantially over time. The number has increased 4 fold from Year 1950 to 
1990, with a particularly steep rise since the mid 90s (Engelgau et al., 2004). It is 
estimated that between Year 2000 and 2050, the number of people in the United 
States diagnosed with diabetes will rise from 12 million to 39 million, representing a 
2.3 fold increase (Engelgau et al., 2004). 
The World Health Organization (1999) recognizes three main types of 
diabetes mellitus: Type 1 diabetes [including older terms like childhood-onset 
diabetes, juvenile-onset diabetes and insulin-dependent diabetes mellitus (IDDM)] 
caused by autoimmune destruction of insulin producing p-cells in the pancreas. Type 
2 diabetes [including adult-onset diabetes, obesity-related diabetes and 
non-insulin-dependent diabetes mellitus (NIDDM)] mainly caused by resistance to 
insulin. The third type is gestational diabetes. These 3 types of diabetes may share 
some similar symptoms but have different causes and population distributions. 
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1.1.1. Type 1 diabetes mellitus 
Type 1 diabetes represents 10% of cases of diabetes mellitus. The peak 
incidence is in between 10 and 14 years old, thus, it is also called juvenile-onset 
diabetes mellitus. There are genetic and environmental influences on the 
development of type 1 diabetes. Genetic predisposition probably accounts for 
one-third of susceptibility to type 1 diabetes. The average risk for siblings of type 1 
diabetic patients is about 6%, but the concordance rate for genetically identical 
monozygotic twins is as high as 36% (Risch, 1987; Olmos et al.’ 1988). However, in 
more than 90% of cases, there is no family history of diabetes (EURODIAB ACE 
study group, 1998). It is likely that environmental factors trigger type 1 diabetes in 
genetically susceptible individuals. 
There are over 20 different loci in the human genome associated with 
susceptibility to type 1 diabetes (Davies et al., 1994; Concannon et al” 1998; Mein 
et al., 1998; Cox et al., 2001). The strongest linkage with type 1 diabetes is shown to 
be the IDDMl locus, which encompasses the human leucocyte antigen (HLA) gene 
cluster in the major histocompatibility complex (MHC) on chromosome 6p21 
(Davies et al., 1994). The MHC region contains three important genetic loci: 
HLA-DR, HLA-DP and HLA-DQ. Among these loci, HLA-DQ is found to be 
highly associated with type 1 diabetes (Todd et al., 1988; Undlien et al., 1997). On 
the other hand, population studies reveal that dominant protection against diabetes is 
conferred by HLA-DQ6 and DQ18 antigens (Cavan et al., 1993; Pugliese et al., 
1995). 
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A number of autoantibodies specific for pancreatic p-cells is also found 
to be involved in the development of type 1 diabetes. Islet-cell autoantibodies and 
glutamic acid decarboxylase autoantibodies are present in up to 70-80% (Schranz et 
al., 1998; Lemmark, 1999; Notkin and Lemmark, 2001), insulinoma-associated-2 
autoantibodies in 50-60% (Lan et al., 1996) and insulin autoantibodies in about 40% 
(Yu et al., 2000) of patients with newly diagnosed diabetes. Expression of more than 
one of these autoantibodies is a high risk factor in developing type 1 diabetes. 
1.1.2. Type 2 diabetes mellitus 
Type 2 diabetes is the most common form of the disease, accounting for 
90% of all cases worldwide and affecting 5-7% of the world's population. It is 
estimated that global prevalence will double between Year 1995 and 2025, and 
increase to 270 million people (King et al., 1998). 
Genetic predisposition accounts for 40-80% of susceptibility to type 2 
diabetes and it is polygenic. Genetic factors may influence insulin resistance and/or 
secretion (Nesher et al., 1987; Polonsky et al., 1996). Most genetic information 
about type 2 diabetes is based on highly familial monogenic forms, such as Maturity 
Onset Diabetes of the Young (MODY), which accounts for 2-5% of type 2 diabetes 
(King et al., 1993). MODY is characterized by autosomal dominant transmission, 
with onset usually in children or adolescent (Hani et al., 1999; Fajans et al., 2001), 
and presents with insulin-secretion defects (Froguel and Velho, 1999). 
Candidate genes associated with type 2 diabetes include genes with 
insulin promoter, insulin genes with class III alleles in the upstream region (Dunger 
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et al.，1998; Huxtable et al.’ 2000), and genes that encode transcription factors and 
peroxisome proliferator-activated receptor-y (Altshuler et al., 2000). Locus for type 
2 diabetes is found at chromosome 2q, which encodes calpain-10 (a non-lysosomal 
cysteine protease), but its possible role is still unclear (Horikawa et al., 2000). 
Other than genetic factors, environmental risk factors, especially obesity 
« 
(accounting for 90% of acquired risk) and physical inactivity (Chan et al., 1994; 
Colditz et al., 1995) also play a major role in induction of type 2 diabetes. Obesity, 
especially with abdominal and visceral fat accumulation, induces insulin resistance 
(Kolterman et al., 1980; Bonadonna et al., 1990), which is associated with glucose 
intolerance (Laine et al., 1998) and cardiovascular risk factors in the metabolic 
syndrome (Westerbacka et al” 1999). 
1.1.3. Gestational diabetes 
Gestational diabetes mellitus (GDM) occurs in about 2-5% of all 
pregnancies. According to American Diabetes Association (2002), the prevalence of 
hyperglycemia during pregnancy is between 1-14%. GDM usually appears in the 
second half of pregnancy and mainly affects fetal growth rate rather than 
organogenesis (Catalano et al., 1995). Clinical studies show that common risks for 
GDM include age over 30’ family history of diabetes mellitus and obesity (Cypryk 
et al., 2005; Boriboonhirunsam et al., 2006). 
GDM involves a combination of inadequate insulin secretion and 
responsiveness. The ambient glucose levels are higher in GDM, however, insulin 
response per unit of glycemic stimulus is only half of that observed in normal 
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pregnancy (Hormes et al.，1981). p-cell sensitivities to both glucose and amino acids 
are significantly lower in women with GDM, as a result, insulin secretion becomes 
inadequate (Kuhl, 1991). Even though it may be transient, GDM can damage the 
health of both the mother and the fetus. Mild blood glucose abnormalities during 
pregnancy may be linked to later glucose tolerance abnormalities or diabetes 
mellitus (Vambergue et al., 2007). About 20-50% of women with GDM develop type 
2 diabetes later in life (Kim et al., 2002). 
Recent research findings showed that menin, a protein characterized as 
an endocrine tumor suppressor and transcriptional regulator, was critical in 
controlling islet growth in pregnant mice (Kamik et al., 2007). Pregnancy-stimulated 
proliferation of maternal pancreatic p-cells was accompanied by reduced islet menin 
level. Transgenic expression of menin in maternal p-cells prevented islet expansion 
and led to symptoms of GDM, such as hyperglycemia and impaired glucose 
tolerance (Kamik et al., 2005; Kamik et al., 2007) 
1.2. DIABETIC PREGNANCY 
Pregestational diabetes, including type 1 and type 2, can adversely 
affect the fetus by causing developmental malformations. The longer the mother had 
the disease, the higher the incidence rate of malformations in the fetus (Chung and 
Myrianthopoulos, 1975b). As for GDM, although it mainly affects fetal growth but 
not organogenesis, increased risk for congenital anomalies has also been reported 
(Martinez-Frias et al., 1998). 
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According to National Statistics (2004), the overall perinatal mortality 
rate has fallen in England and Wales over the past 70 years. However, prenatal 
mortality and stillbirth rates remain about four times higher in diabetic than in 
non-diabetic pregnancies. Indeed, congenital malformations are the major cause of 
morbidity and mortality in infants bom to diabetic pregnant women (Reece and 
Homko, 2000; Suhonen and Hiilesmaa, 2000). Despite considerable advances in 
diabetic management, the congenital malformation rate associated with diabetic 
pregnancies remains three to five times higher than in the general population 
(Casson et al., 1997; Hawthorne et al.，1997). The most common malformations 
found are cardiovascular and genitourinary defects, accounting for 60% of 
anomalies (Rowland et al., 1973; Galindo et al., 2006). Other anomalies involve 
skeletal system (Passarge and Lenz, 1966) and central nervous system (Piatt and 
Golde, 1983). Among all malformations, caudal regression (also commonly called 
caudal agenesis, caudal dysgenesis or sacral agenesis) is the most characteristic 
anomaly associated with diabetes (Kucera, 1971, Martinez-Frias, 1994; Zaw and 
stone, 2002; Singh et al., 2005). Recent study showed that there was a positive 
correlation between increased hemoglobin HbA(lC) levels and the rate of fetal 
malformations. Women with early maternal HbA(lC) concentrations over 7% 
showed a three to five fold increase in fetal malformation rates than women with 
normal pregnancy (Galindo et al., 2006). 
Apart from congenital malformations, diabetic pregnancy is also 
associated with spontaneous abortion. Pregnant women with type 1 diabetes and 
higher levels of blood glucose glycosylated hemoglobin in the first trimester of 
pregnancy have a higher risk for spontaneous abortion (Kalter, 1987; Greene et al., 
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1989; Hanson et al., 1990; Greene, 1999). Recent study showed that knockout mice 
of peroxisome proliferator-activated receptor alpha {PPARa) together with maternal 
diabetes led to a significant increase in the abortion rate than those in non-diabetic 
pregnancy, suggesting that PPARa deficiency will enhance maternal abortion in 
diabetic conditions (Yessoufou et al., 2006). 
Congenital malformations associated with diabetic pregnancy also 
involve genetic factors. In human cases, it is found that Caucasians have 
significantly higher incidences in certain types of malformations, such as congenital 
dislocation of the hip, micrognathia and pectus excavatum, over Negroes (Chung et 
al., 1975a). Animal studies also provide evidence that susceptibility to congenital 
malformations is dependent on both the maternal and fetal genomes. For instance, 
different rat strains display different types of diabetes-related malformations 
(Eriksson, 1988; Tanakao et al., 1991). 
Fetal growth depends on nutrient transfer from mother to fetus, which is 
determined by placental size, uterine blood flow and nutrient supply. All these 
factors can be influenced by maternal diabetes (Hay, 1991). Infants of diabetic 
mothers are often growth promoted or large-for-gestational-age (Bradley et al., 
1988). This may be due to increased matemo-fetal nutrient transfer. The availability 
of glucose, amino acids and lactate to the fetus is increased under diabetic pregnancy 
(Challier et al., 1976). Glucose and some amino acids, including arginine and 
leucine are p-cell secretagogues, and thus contribute to fetal hyperinsulinaemia 
(Schwartz and Susa, 1980). The frequency of large-for-gestational-age infants in 
diabetic pregnancy is approximately twice as high as in non-diabetic ones, especially 
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in pregnancies of type 2 and GDM (Green et al.，1991; Ray et al.，2001). Fetuses of 
diabetic pregnancy exhibit alteration of pancreatic p-cells and islets development, 
resulting in accelerated and inappropriate growth (macrosomia). 
Maternal diabetes also affects the placenta. It was shown in a 
streptozotocin-induced diabetic rat model that oxidative stress in placental tissues 
caused abnormal placental structure and function (White et al., 2002). High glucose 
levels in diabetic conditions exert an auto-regulatory effect on hexose transport in 
the placental trophoblast by altering glucose transporter-1 (GLUT-1) partitioning 
between the plasma membrane and intracellular sites (Hahn et al., 2000). Besides, 
glucose transporters (including GLUTl, GLUT2 and GLUTS) were found to be 
down-regulated at the blastocyst stage in diabetic mice (Moley, 1999). This 
down-regulation decreased glucose transportation into the blastocyst of diabetic 
mice and thus lowering the intraembryonic free glucose level, thereby inducing 
apoptosis. Moreover, as shown in animals, hyperglycemia inhibits trophoblast 
proliferation, providing a potential mechanism for early intrauterine growth delay in 
poorly controlled diabetes (Weiss et al” 2001). 
1.3. ETIOLOGY OF DIABETES-INDUCED MALFORMATIONS 
What mediates the teratogenicity of maternal diabetes is not yet 
precisely known. A variety of metabolic disturbances including hyperglycaemia, 
hyperketonaemia, nutritional deficiencies as well as many other non-genetic and 
genetic factors affect embryo development during diabetic pregnancy. Hence, the 
concept of multifactorial origins has been proposed to explain the pathogenesis of 
diabetic embryopathy (Sadler et al., 1989; Reece et al., 1996). 
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1.3.1. Hyperglycaemia 
Hyperglycaemia has been demonstrated to be teratogenic in animal 
models (Kalter and Warkany, 1983, Freinkel et al., 1988). The critical period of 
vulnerability to teratogens is the stage of organogenesis. 
Embryos cultured in rat serum supplemented with D-glucose exhibited 
malformations (Pinter et al, 1986). The rate of malformations could be enhanced by 
increasing the concentration of glucose in the culture medium (Reece et al.，1996). 
Many human clinical studies show that there is a positive relationship between risk 
of congenital malformations and poor glycemic control (Miller et al., 1981; Lucas et 
al., 1989; Suhonen and Hiilesmaa, 2000). In infants bom to diabetic mothers, 
malformation rate is about 2.7-16.8%, while in that of non-diabetic mothers, it is 
only 2-3% (Lemons et al., 1981; Key et al., 1987). Moreover, hyperglycemia was 
found to over-express proapoptotic protein BAX and induce p53-mediated 
apoptotsis in the preimplantation mouse embryo, which triggered spontaneous 
abortion (Keim et al., 2001). Oocytes from hyperglycemic animals developed 
several abnormalities in later stages, which might also be due to programmed cell 
death (Doblado and Moley, 2007; Gareskog et al., 2007). However, it has been 
shown that adequate glycemic control during the first trimester of pregnancy could 
significantly reduce the incidence of diabetes-associated congenital anomalies 
(Fuhrmann et al., 1983; Fuhrmann et al.，1984; Kitzmiller et al., 1991). 
1.3.2. Hyperketonaemia and somatomedin inhibitors 
Hyperketonaemia is also implicated as a teratogen in pregnancies 
complicated by diabetes (Freinkel, 1988). Infants of hyperketonaemic mothers have 
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shown an increased rate of congenital malformations and mental impairment 
(Jovanovic-Peterson and Peterson, 1991; Jovanovic et al.，1998). Rat embryos 
cultured in high concentrations of p-hydroxybutyrate showed growth retardation and 
malformations (Horton and Sadler, 1983). 
In diabetes, levels of somatomedins (a hormone that promotes cell 
growth and cell division) in serum measured by radio-assay are normal, yet, 
somatomedin activity measured by bioassay is relatively low. This discrepancy is 
due to the fact that bioassay measurement reflects the presence of both 
somatomedins and somatomedin inhibitors (Phillips et al., 1985). Somatomedin 
inhibitors are found in high concentrations in streptozotocin-induced diabetic 
animals, and therefore have been implicated as an etiologic factor in diabetic 
embryopathy (Phillip et al., 1979). Rat embryos cultured in the presence of the 
low-molecular-weight fraction of somatomedin inhibitors were found to be 
associated with an increased incidence of malformations and impaired growth 
(Sadler et al, 1986). 
1.3.3. Oxidative stress 
Patients with diabetes show a significant increase in free oxygen 
radicals formation in the blood (Soska et al., 1993) and increased generation of 
oxidative stress in the mitochondria of vascular endothelial cells (Nishikawa et al., 
2000). Oxidative stress can inhibit expression of genes that control essential 
developmental processes. For example, it has been suggested that oxidative stress 
inhibited PaxS that suppressed p53-dependent cell death, as a result, extensive 
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apoptosis occurred in the neuroepithelium and led to neural tube defects (Loeken, 
2006). 
In vitro studies showed that hyperglycaemia led to embryopathy via 
generation of free oxygen radicals (Eriksson et al., 1990). On the other hand, adding 
free oxygen radical scavenging enzymes superoxide dismutase (SOD) to rat 
embryos cultured under hyperglycaemic conditions could reduce the malformation 
rate (Eriksson and Borg, 1991). Moreover, elevated levels of SOD provided by a 
Cu/Zn superoxide dismutase transgene in mice enhanced the tolerance of pancreatic 
p-cells to oxidative stress-induced diabetogenesis (Kubisch et al., 1994). 
Supplementation with antioxidants, such as butylated hydroxytoluene (Eriksson and 
Siman, 1996), vitamin C (Siman and Eriksson, 1997a) and vitamin E (Sivan et al., 
1996; Siman and Eriksson, 1997b; Cederberg et al., 2001) could also normalize 
development of the offspring in diabetic pregnancy (Cederberg and Eriksson, 2005). 
Recent findings showed that high glucose levels in diabetic conditions 
inhibited glyceraldehydes-3 -phosphate dehydrogenase (GAPDH), leading to excess 
of reactive oxygen species (ROS) in the embryo. This enhanced the activity of polyl 
pathway and protein kinase C (Wentzel et al., 2003) that were found to be correlated 
with development of malformations (Hiramatsu et al., 2002). 
1.3.4. Deficiency of myo-inositol and arachidonic acid 
Hyperglycaemia-induced abnormalities of myo-inositol and 
phosphoinositide metabolism have also been suggested to play a role in 
diabetes-related malformations (Hod et al., 1990). Studies showed that in embryos 
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from streptozotocin-induced diabetic rats that had dietary supplementation of 
myo-inositol (Khandelwal et al.，1998), or in embryos cultured in vitro in 
hyperglycaemic conditions supplemented with myo-inositol (Hashimoto et al., 1990)， 
there were significant reductions in the risk of malformations and growth 
retardation. 
Prolonged diabetes induces alterations in fatty acid composition of 
phospholipids in tissues. In particular, there is a decrease in the relative level of 
arachidonic acid (Holman et al., 1983; Hu et al., 1994). Alteration of arachidonic 
acid metabolism under hyperglycemia leads to altered production of prostaglandins 
and generation of nitric oxide, which can enhance production of ROS (Jawerbaum 
and Gonzalez, 2005). Supplementation of arachidonic acid to embryos cultured in 
high glucose could prevent malformations and microscopic abnormalities of the yolk 
sac (Pinter et al., 1988). 
1.4. VITAMIN A 
Other than those biochemical anomalies mentioned above, plasma 
vitamin A (retinol) level is also found altered under diabetes. Children and adult 
patients with type 1, but not type 2 diabetes, have reduced serum levels of vitamin A 
(Basu et al., 1989; Havivi et al.，1991; Straub et al., 1993). Rats made diabetic with 
streptozotocin (a drug that specifically kills pancreatic p-cells) also showed reduced 
plasma vitamin A levels (Basu et al., 1989; Tuitoek et al., 1996; Lu et al., 2000). In 
cases of poorly controlled type 1 diabetes, the bioavailability of retinol is even much 
lower (Basu et al., 1989). 
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Vitamin A is an essential lipid-soluble nutrient crucial for maintaining 
pregnancy and morphogenesis of most developing organs and tissues (Clagett-Dame 
and Deluca, 2002). The mammalian fetus acquires vitamin A from maternal 
circulation, in which retinol is transported in association with retinol binding protein 
(RBP). Zinc is an important ion in the synthesis of RBP (Smith et al., 1974). 
Diabetes-induced hyperzincuria results in depletion of zinc and RBP levels in the 
plasma, affecting metabolic availability of retinol (Honnorat et al., 1992). Studies of 
rats showed that offspring bred on a vitamin A-deficient diet died before or at birth, 
and embryos usually showed defects in the hindbrain (Maden et al., 1995; White et 
al.，2000) and apoptosis in neural crest cells (Halilagic et al., 2003). Besides, a 
spectrum of malformations that affected the eye, skeletal system, thyroid, thymus, 
heart, lung and branching organs was also found (Mason, 1935; Wilson and Warkany, 
1948; Wilson et al., 1953). These defects were similar to those exhibited by fetuses 
developed in diabetic pregnancies as previously mentioned in section 1.2. 
The most biologically active form of vitamin A is dXX-trans retinoic acid 
(RA) (Vogel et al., 1999), which regulates the transcription of many developmental 
genes (Balmer and Blomhoff’ 2002). 
1.5. RETINOIC ACID 
RA is found to be present in most embryonic tissues (McCaffery and 
Drager, 1994; Horton and Maden, 1995). It is one of the first morphogens identified 
with an anterior-posterior gradient in chick and amphibian forelimb bud (Thaller and 
Eichele, 1987; Scadding and Maden, 1994) and is the key signaling molecule that 
governs many embryonic developmental processes. It is a rapidly diffiising signaling 
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molecule that can specify cell identities and control gene expression through 
activation of specific nuclear receptors (Leid et al., 1992). 
1.5.1. RA signaling on embryo development 
RA signal transduction is mediated via two types of nuclear retinoid 
receptors, which are retinoic acid receptors (RAR) and retinoid X receptors (RXR). 
RA carries out its signaling activity by binding to RAR, which form homodimers or 
heterodimers with RXR, and function as ligand-inducible transcriptional regulators 
(Leid et al., 1992; Mangelsdorf and Evans, 1995). This complex can bind to the 
retinoic acid response element (RARE), which is typically located in the promoter 
region of target genes, to activate or suppress gene transcription (Baimer and 
Blomhoff，2002). Both RAR and RXR have 3 subtypes: a, p, y. There are multiple 
isoforms in each subtype. Different isoforms express in different tissues and at 
different developmental stages (Dolle et al., 1990; Ruberte et al., 1990; Matt et al., 
2003). Study on a mouse strain carrying a RA-activated reporter transgene shows 
that RA does not distribute homogeneously throughout the embryo, but is localized 
to specific regions within a restricted number of developing organs (Balkan et al., 
1992). RA signaling is involved in diverse biological processes such as limb 
patterning (Eichele, 1989), craniofacial development (Rowe et al., 1992) and central 
nervous system patterning (Maden and Holder, 1992). 
1.5.2. RA teratogenicity 
RA causes dysmorphogenesis through interference of one or more 
cellular events, such as cell proliferation, apoptosis, differentiation, adhesion and 
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migration (Kochhar, 2000). One of the mechanisms of RA teratogenicity is via 
alteration of Hox genes expression which is important for specification of cell 
identity along the anterior-posterior axis of the embryonic central nervous system 
(Boncinelli et al., 1991, Schubert et al., 2006). For example, expression of Hox-2 
genes (including Hox-2.9, Hox-2.8 and Hox-2.6) was found to be ectopically 
induced in the anterior region in mouse embryos upon maternal treatment with RA 
on day 8 of gestation. Altered patterns of expression of these genes induced 
transformation of the anterior hindbrain to posterior hindbrain, affecting both 
rhombomeric segmentation and rhombomere-specific gene expression (Morriss-Kay 
et al., 1991, Conlon and Rossant, 1992). Many of the Hox genes are also 
downstream targets of RA receptors, for instance, Hoxa-1 (Dupe et al., 1997), 
Hoxb-1 (Marshall et al., 1994)，Hoxb-4 (Gould et al., 1998) and Hoxd-4 (Zhang et 
al., 2000). Their expressions were found to be affected by RA signaling in both cell 
lines (Simeone et al., 1990; Simeone et al., 1991) and embryonic tissues 
(Morriss-Kay et al., 1991; Conlon and Rossant, 1992). Up-regulation of these genes 
was observed in embryos upon RA treatment. Besides, Hox genes play an important 
role in patterning of limbs, vertebrae and craniofacial structures (Kessel et al., 1990; 
Chisaka et al., 1992; Morgan et al., 1992). 
Other than Hox genes, RA teratogenicity affects different organs via 
various genes, for example, exogenous RA can down-regulate fibroblast growth 
factor-4 {Fgf4) which is important for limb bud outgrowth (Hayes and Morriss-Kay, 
2001). Increase in RA levels in the limb bud of mouse embryos has been shown to 
cause limb anomalies (Satre and Kochhar, 1989). However, knockout of RXRa 
could in turn make embryos resistant to RA-induced limb defects (Sucov et al” 
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1995). Recent findings showed that treatment of mouse embryos with Retinoic Acid 
Metabolic Blocking Agents (RAMBAs) could raise endogenous RA levels and 
caused abnormalities that were similar to those found in knockout mice of RA 
catabolizing genes (Abu-Abed et al., 2001; McCaffery and Simons, 2007). 
Furthermore, it has been shown that excess RA could arrest cranial 
neural crest cells proliferation and migration (Johnston et al., 1985; Goulding and 
Pratt, 1986). In RA-treated mouse embryos that exhibited caudal axial defects, 
expressions of cell surface and extracellular matrix glycoconjugates in the tail bud 
were altered (Griffith and Wiley, 1990). 
Other than excess of RA, insufficiency of RA is also teratogenic. 
Administration of citral (inhibitor of RA synthesis) to mouse embryos at day 9.5 of 
gestation induced branchial arch and cranial nerve defects (Di Renzo et al., 2007). 
Loss of RA can also affect somitogenesis (Duester, 2007). RA is required to 
suppress the posterior ectodermal expression offibroblast growth factor-8 (FgfS) for 
a short period of time during the late primitive steak stage when the somitogenesis 
clock initiates. Decrease in RA levels will trigger FgfS signaling in presomitic 
mesoderm and leads to left-right asymmetry during somitogenesis and causes 
vertebral birth defects such as scoliosis (Duester, 2007). 
1.5.3. RA regulation 
Studies on RA homeostasis in the embryo indicate that the 
RA-synthesizing and catabolizing enzymes are localized to different regions of the 
developing embryo (Niederreither et al., 1997; White et al., 1997; Moss et al., 1998). 
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Expression domains of RA-synthesizing enzymes are similar to the sites of 
localization of RA in the embryo (Rossant et al, 1991). Synthesis of RA begins with 
the conversion of retinol to retinaldehyde via alcohol dehydrogenases. This is 
followed by conversion of retinal to RA, mediated by the enzyme retinaldehyde 
dehydrogenases (RALDH), which is the rate limiting step in RA synthesis. Among 
the three identified RALDH (RALDH 1, RALDH2 and RALDH3), RALDH2 has the 
highest substrate specificity in synthesizing RA and its distribution provides the 
most accurate guide to the localization of RA in the embryo, including expression in 
the spinal cord, motoneurons and developing eyes (Moss et al., 1998，Niederreither 
et al., 2002). This suggests that a significant proportion of RA signaling in the 
embryo may rely on localized RA synthesis. Raldhl is indispensable for 
embryogenesis. Raldh2 transcripts are first detectable in the mouse embryo at day 7 
of gestation in the mesoderm adjacent to the primitive streak and later in the somites, 
mesodermal structures in the trunk and the posterior end of the embryo 
(Niederreither et al, 1997; Ulven et al., 2000). Homologous deletion of Raldh2 
results in early lethality. The trunk of the embryo is severely shortened, and the 
neural tube remains open, whereas the anterior region is less affected (Niederreither 
et al., 1999). 
RA catabolism can be mediated via the enzyme CYP26, which is a 
member of the cytochrome P450 family (Fuji et al., 1997). It is suggested that 
CYP26 is responsible for enzymatic inactivation of RA by converting it to more 
polar hydroxylated and oxidized metabolites, including 4-oxo and 4-hydroxy RA 
(White et al., 1997; Abu-Abed et al., 1998) that are not involved in signaling process 
during embryo development (Niederreither et al., 2002). So far, three subtypes of 
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Cyp26 genes have been identified, including Cyp26al, Cyp26bl and Cyp26cl. 
Cyp26al promoter contains two RAREs (Loudig et al., 2000; Loudig et al.，2005)， 
and thus Cyp26al expression can be regulated by RA. However, exposure of mouse 
embryos to RA induced Cyp26al expressions in limited regions (Fuji et al.，1997), 
indicating the existence of other transcriptional regulators for this gene. 
The normal expression pattern of Cyp26al in the embryo is suggestive 
of a function in regulating RA distribution. In the mouse, at day 7.25 of gestation, it 
is present in a posterior to anterior gradient in the mesoderm. High levels of 
expression at the posterior end continue through embryonic day 8.5 to day 11.5. 
Localized areas of anterior expression also exist, with high levels in neural crest 
cells of the hindbrain that migrate to the cranial ganglion (Fuji et al., 1997). In the 
central nervous system, expression is also present in the otic vesicle and the eye. The 
presence of Cyp26al in a midline stripe in the retina between the expression domain 
of two RA synthesizing enzymes, Raldhl and RaldhS in the dorsal and ventral 
regions respectively (McCaffery et al., 1999), suggests a possible role of Cyp26al in 
boundary formation, acting as a perimeter between regions of high RA synthesis 
(Hollemann et al., 1998). Null mutants of Cyp26al exhibit various abnormalities 
and usually die at mid-gestation (refer to section 5.1 for details). 
1.6. R A AND MATERNAL DIABETES-INDUCED CAUDAL 
REGRESSION SHARE SIMILAR PATHOGENIC MECHANISMS 
Caudual regression syndrome is a disorder characterized by different 
degrees of agenesis of the vertebral column, ranging from absence of vertebrae up to 
lower thoracic level or just the missing of a few coccygeal segments (Pang, 1993; 
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Cama et al., 1996). It is sometimes associated with anomalies of the central nervous 
system, genitourinary, cardiac, respiratory and gastrointestinal systems (Duhamel, 
1961). Sirenomelia, an extreme form of caudal regression syndrome is a lethal 
condition characterized by fusion of the lower limbs, single umbilical artery, and 
severe malformations of the urogenital and lower gastrointestinal tracts (Das et al.， 
2002). 
The incidence of caudal regression syndrome is 1 in 7,500 births, and 
males are affected more frequently than females (Rusnak and Driscoll, 1965; Kallen 
and Winberg, 1974). Caudal regression syndrome is found to be the anomaly most 
strongly associated with maternal diabetes (Martinez-Frias, 1994). In diabetic 
pregnancy, the incidence rate of caudal regression syndrome in infants is 75 times 
higher than non-diabetic pregnancy (Passarge and Lenz, 1966; Kucera, 1971). 
The molecular mechanism underlying development of caudal 
regression is not ftilly understood. However, change in RA signaling is found to 
increase the risk. It has been shown in a mouse model that administration of RA to 
pregnant mice on day 9.5 of gestation, which is equivalent to week 4 after 
conception of human pregnancy, could lead to development of caudal regression 
(Shum et al., 1999), with a spectrum of malformations closely resembling cases of 
caudal regression associated with maternal diabetes (Zaw and stone, 2002; Singh et 
al., 2005), suggesting that RA and maternal diabetes may share similar pathogenic 
mechanisms. 
The caudal most part of the embryo is called the tail bud, which 
contains progenitor cells for forming various tissues of the caudal part of the body 
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including the lower vertebral column. It has been shown that Wnt-Sa, which 
expresses specifically in the tail bud, is indispensable for caudal development 
(Takada et al., 1994). Null mutation of Wnt-3a results in failure of caudal 
development, with truncation of the body axis caused by apoptosis of the progenitor 
cells at the tail bud region of the embryo (Takada et al., 1994; Greco et al., 1996). 
Wnt-3a was found to be down-regulated in the tail bud region of embryos after RA 
treatment (Shum et al., 1999). Moreover, it has been shown that embryos of diabetic 
mice were more susceptibile to RA-induced caudal regression than embryos of 
non-diabetic mice (Chan et al., 2002). This was accompanied by enhanced 
down-regulation of Wnt-3a and exacerbated cell death in the tail bud of embryos of 
diabetic mice after RA treatment (Chan et al., 2002), thus suggesting that maternal 
diabetes might potentiate the teratogenic effect of RA. 
The teratogenic effect of RA is highly dose-dependent. As discussed in 
section 1.5.3, RA concentrations can be regulated by the RA catabolizing enzyme 
CYP26. Mouse mutants with homologous disruption of Cyp26al, one of the 
subtypes of Cyp26, developed caudal regression (Abu-Abed et al.，2001), with a 
spectrum of abnormalities very similar to those caused by excess RA (Sulik et al., 
1995; Kochhar 2000) and maternal diabetes (Casson et al” 1997; Singh et al., 2005; 
Allen et al., 2007), suggesting that some common pathogenic mechanisms may exist 
among them. 
1.7. STRATEGY OF THE THESIS 
Our laboratory has recently demonstrated that embryos of diabetic mice 
showed significantly lower expression levels of Cyp26al in comparison to embryos 
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of non-diabetic mice (Leung, 2005). As mentioned in section 1.5.3, Cyp26 mediates 
RA catabolism in normal embryogenesis. Whether alteration of this gene under 
diabetic pregnancy disturbs RA homeostasis and increases the risk for 
malformations remains unclear. The aim of this thesis was to test the hypothesis that 
in diabetic pregnancy, down-regulation of Cyp26al reduces RA catabolism and 
increases the effective concentration of RA in some developing tissues, thereby 
increasing the risk of RA-induced malformations. To this end, I have used caudal 
regression syndrome, the most characteristic birth defect associated with diabetic 
pregnancy, as a model to investigate the above hypothesis. 
The first part of my project was to test whether RA catabolism in the 
tail bud region of the mouse embryo was mediated via CYP26, the major biological 
RA catabolizing enzyme (Chapter 3). To follow on, I have investigated whether 
there was reduction in RA catabolizing activity in the tail bud region of embryos of 
diabetic mice, as our laboratory has previously found that Cyp26al was significantly 
down-regulated in this tissue. To achieve this, I have compared RA catabolism by an 
in vitro and an in vivo approaches. In the in vitro approach, the tail bud region of 
embryos of diabetic and non-diabetic mice was excised and placed in RA containing 
medium to test for its RA catabolizing activity. In the in vivo approach, diabetic and 
non-diabetic pregnant mice were injected with RA and the concentration of RA in 
the tail bud region of the embryo was monitored at regular intervals to determine the 
rate of removal of RA. 
After establishing the fact that under maternal diabetes, RA catabolism 
was decreased and such decrease was mainly contributed by CYP26, in the second 
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part of my project (Chapter 4)，I have investigated whether diabetes-induced 
alteration of Cyp26 was specific to Cyp26al. I have examined the expression level 
of the three subtypes of Cyp26 genes, including Cyp26al, Cyp26bl and Cyp26cl, 
and found that Cyp26al was predominantly expressed and down-regulated in the tail 
bud region under diabetes, while the other two subtypes showed very low level of 
expressions and were not altered in diabetic pregnancy. Next, I have compared the 
change in expression levels of Cyp26al in the tail bud region of embryos of diabetic 
and non-diabetic mice after maternal treatment with RA to determine if there was 
any correlation with results in Chapter 3 on change of RA levels. 
In the last part of my project (Chapter 5), I have compared three 
parameters, (i) Cyp26al expression levels in the tail bud region, (ii) RA 
concentrations in the tail bud region after maternal treatment with RA and (iii) 
susceptibility to RA-induced caudal regression, between Cyp26al heterozygous 
embryos and their wild-type littermates developed in diabetic and non-diabetic 
pregnancies. The relationship of these three factors was analyzed to determine if a 
decrease in Cyp26al expression levels under diabetic pregnancy would increase RA 
concentrations in the tail bud tissue and thus enhanced the embryo's susceptibility to 
caudal regression. 
Finally, in Chapter 6, results of this study were concluded and future 
perspectives were discussed. 
- 2 3 -
Chapter 2 
General Materials and Methods 
- 2 4 -
Chapter 2: General Materials and Methods 
2.1. ANIMAL 
The ICR (Institute of Cancer Research) mouse colony and the Cyp26al 
knockout mouse colony in C57BL/6Cr background (Sakai et al., 2001) were 
established from breeding pairs originally obtained from Harlan, UK and Prof. 
Hiroshi Hamada respectively. They were random-bred at Laboratory Animal 
Services Centre (LASEC) of the Chinese University of Hong Kong. Mice were fed 
with irradiated LabDiet for Rodents {PMI Nutrition) and ozone-sterilized tap water. 
All animal experimentation procedures were approved by the Animal 
Experimentation Ethics Committee of the Chinese University of Hong Kong. 
Mice were kept in a humidity and noise-controlled room running on a 
12:12 hr light-dark cycle with the dark period starting from 11:00 pm to 11:00 am. 
One female mouse was paired up with one male mouse for 2 hours (hr) from 9:00 
am to 11:00 am. At 11:00 am, the female mouse was examined for the presence of a 
copulation plug in the vagina. Fertilization was assumed to occur at 10:00 am and 
this time point was considered as day 0 of gestation. 
2.2. INDUCTION OF DIABETES 
Diabetes was chemically induced in 8-week-old ICR female mice by 
intraperitoneal injection with 65 mg/kg body weight of streptozotocin {ICN) at 4:00 
pm for three consecutive days. Streptozotocin was freshly prepared by dissolving in 
0.01 M sodium citrate buffer (pH 4.5) prior to injection. Mice were screened for 
diabetes 12 days after the first day of injection. The glucose level of blood sample 
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taken from the tail vein was measured using a glucometer (Glucometer Elite, Bayer). 
Mice with blood glucose level higher than 16.5 mmol/L were classified as diabetic 
and used for experiments, whereas mice with blood glucose level lower than 16.5 
mmol/L were discarded. In general, about 75% of induced mice would become 
diabetic. Untreated age-matched female mice were used as the non-diabetic control. 
The blood glucose level of the diabetic pregnant mouse was measured on the day of 
sacrifice to ensure that the mouse remained diabetic during pregnancy. 
2.3. PREPARATION OF RETINOIC ACID FOR MOUSE INJECTION 
A\\-trans retinoic acid (RA, Sigma) was prepared as a stock solution at 
a concentration of 3.33 mg/ml. First, RA at a weight of 50 mg, was dissolved in 1.5 
ml of absolute ethanol {BDH) by vigorous vortexing for 2 hr. The RA solution was 
then suspended in peanut oil {Sigma) to a final volume of 15 ml by vigorous 
vortexing for another 2 hr. To prevent photo-oxidation, RA was kept in a tube 
wrapped with aluminum foil throughout the process. Different concentrations of RA 
suspension were prepared by further dilution with peanut oil, such that mice being 
treated with different dosages of RA were injected with an equivalent volume of RA 
suspension. The RA suspension was stored at 4°C and used within 2 weeks. 
2.4. R A RESPONSIVE CELL LINE 
The RA responsive cell line, a gift from Dr. Peter McCaffery, was 
derived from the F9 teratocarcinoma cell line that has been stably transfected with 
the P-galactosidase gene with its expression under the control of the RARE of 
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RARp (Wagner et al., 1992). It expresses different levels of p-galactosidase in 
response to different concentrations of RA. 
2.4.1. Cell culture 
Cells stored in sealed plastic ampule under liquid nitrogen were 
immediately thawed in a water bath at 37°C. As soon as the cell deforzed, the 
ampule was sterilized with 70% ethanol and opened with a sterilized knife. The 
thawed cell was pipetted out and mixed with 10 ml of Hanks' medium (Gibco) to 
dilute the toxic effect of dimethyl sulfoxide (DMSO) present in the freezing medium. 
The cell suspension was centrifuged at 3,000 revolutions per minute (rpm) for 3 
minutes (min). The supernatant was discarded and the cell pellet was resuspended in 
5 ml of culture medium, composing of Dulbecco's Modified Eagle's Medium 
(DMEM, Gibco) supplemented with 10% fetal bovin serum {Gibco), 2 mg/ml G418 
(Sigma), 100 units/ml penicillin G (Sigma) and 0.1 mg/ml streptomycin (Sigma). 
The cell was grown on 25 cm^ culture flask (Nunc) in a 5% CO2 incubator at 3TC. 
The culture flask was coated with gelatin. This was done by coating the culture flask 
with 0.10/0 gelatin solution for half an hour at 37°C followed by washing once with 
Hanks' medium prior to use. 
To detach cells from the surface of the culture flask, cells were 
incubated with 3 ml of trypsin at 3TC for 1 min. The reaction was stopped by 
mixing the cell suspension with 10 ml of culture medium. The cell suspension was 
centrifuged at 3,000 rpm for 3 min. The supernatant was discarded and the cell pellet 
was re-suspended in culture medium for later use. The cell density in the 
re-suspended medium was evaluated by cell counting using hematocytometer. 
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2.4.2. Seeding and adding sample to 96-well plate 
To culture the RA responsive cell on the 96-well plate {Nunc), the plate 
was first incubated with 0.1 % gelatin for half an hour and then washed with Hanks' 
medium. Cells were seeded onto the gelatin-coated 96-well plate at a density of 4 
xl04 cells in 100 )il of culture medium per well and allowed to grow until 80% 
confluence (usually took about 16 hr of incubation after seeding). 
To analyze the relative amount of RA in the sample, 80 |LI1 of the RA 
containing sample was added to each well. Each sample was tested in triplicate for 
accurate quantification. Cells were incubated in a 5% CO2 incubator at 37°C to 
allow transcriptional activation of the p-galactosidase reporter gene. 
2.4.3. Staining of cells 
The induction level of p-galactosidase was quantified by its activity to 
convert the substrate 5-bromo-4-chloro-3-idolyl-p-galactopyranoside (X-gal, Gibco) 
into a coloured product. In brief, cells were fixed with 1% glutaraldehyde in 
phosphate buffered saline (PBS) for 10 min and then washed 3 times with 200 )LI1 of 
0.1 M PBS. They were incubated at 37°C for 16 hr, with 70 \x\ per well of staining 
solution consisting of 0.1 M PBS with 3.3 mM K4Fe(CN)6. 3H2O, 3.3 mM 
K3Fe(CN)6.3H20, 6 mM MgCl: and 2 mg/ml X-gal {Gibco, dissolved in dimethyl 
formamide as 40 mg/ml aliquots). At the end of incubation, the staining solution was 
removed. Cells were washed 3 times with 200 [x\ of 0.1 M PBS. The stained cell 
could be kept permanently in 75% glycerol at 4°C or room temperature. The level of 
transcriptional activation of the p-galactosidase reporter gene was quantified as 
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colorimetric readings by an ELISA plate reader (SpectraMax25, Biomolecular 
Device) at wavelength of 650 nm. 
2.5 . REAL-TIME QUANTITATIVE REVERSE TRANSCRIPTION-
POLYMERASE CHAIN REACTION ( R T - P C R ) 
2.5.1. Collection and storage of tissues 
Samples were dissected out in diethylene pyrocarbonate 
(DEPC)-treated RNase-free ice-cold PBS. The embryonic tissue was immediately 
kept in 10-fold volume of RNAlater RNA Stabilization Reagent {Qiagen) at 4°C 
overnight to allow full penetration of the reagent into the tissue. The tissue was 
stored at -20°C until used. 
2.5.2. Total RNA extraction 
Total RNA was extracted by using the RNeasy Mini Kit {Qiagen) 
according to the manufacturer's protocol. In brief, the RNAAa仗r RNA Stabilization 
Reagent was removed. The tissue was lysed in 600 of Buffer RLT (provided in 
the kit) containing 1% beta-mercaptoethanol {BDH) by passing through a 25G 
needle fitted onto a one ml syringe several times. Subsequently, 600 [i\ of 70% 
ethanol was added to the lysate and was immediately mixed by pipetting up and 
down. The lysate mixture was added to the RNeasy mini column (provided in the kit) 
and centrifUged at 13,000 rpm for 30 seconds (sec). After discarding the 
flow-through, 700 |al of Buffer RWl (provided in the kit) was applied to the RNeasy 
column and centrifuged at 13,000 rpm for 30 sec. Again, the flow-through was 
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discarded, followed by addition of 500 ]i\ of Buffer RPE (provided in the kit) and 
centrifuged at 13,000 rpm for 30 sec. This procedure was repeated once. The 
flow-through was discarded and centrifuged at 13,000 rpm for 1 min to eliminate 
any carryover of Buffer RPE. The RNeasy column was transferred to a new 1.5 ml 
microftige tube. To elute the RNA, 50 \x\ of RNase-free water was added directly 
onto the RNeasy silica-gel membrane. After 2 min, the microfuge tube with the 
column was centrifuged at 13,000 rpm for 1 min to collect the RNA in the 
flow-through. Total RNA concentrations were measured by spectrophotometry at 
optical density of 260 nm. 
2.5.3. Reverse transcription 
Total RNA extracted was subject to first-strand cDNA synthesis by 
using the High Capacity cDNA Reverse Transcription Kit {Applied Biosystems). To 
synthesize 10 |LI1 of cDNA solution, 500 ng of total RNA was mixed with 1 i^l of lOx 
Reverse Transcription Buffer, 0.4 of 100 mM dNTP, 1 \x\ of lOx Reverse 
• • 丁 ivi 
Transcription random primers, 0.5 |il MultiScribe Reverse Transcriptase (50 U/jiil) 
and 0.5 fil of RNase Inhibitor (20 U/|al). DEPC-treated water was added to the 
reaction mixture to obtain a final volume of 10 Reverse transcription was 
performed in a thermal cycler (icycler, BioRad) at 25°C for 10 min, followed by 
37°C for 120 min and then 85°C for 5 sec. The cDNA thus synthesized was kept at 
4°C for short-term storage or -20°C for long-term storage. 
2.5.4. Polymerase chain reaction 
The cDNA synthesized was subject to quantitative polymerase chain 
reaction (PGR) using ABI 7500 Fast Real-Time PGR system {Applied Biosystems). 
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Various sets of primers specific for different genes were used. PCR amplification 
was performed in a reaction mixture containing 2 of cDNA, 1 |li1 each of 10 
pmol/^l forward and reverse primers, 10 of 2X POWER SYBR® Green PCR 
Master Mix {Applied Biosystems) and then made up with DEPC-treated water to a 
final volume of 20 |LI1. Each sample was amplified in triplicate for accurate 
quantification. 
For each PCR, a no-template sample was included to serve as the 
negative control, and a set of cDNA standards (refer to section 2.5.5) with known 
quantity was added in duplicate for quantifying the amount of the target gene. 
The PCR conditions started at 95®C for 10 min to activate the 
AmpliTaqGold® polymerase {Applied Biosystems) in the PCR Master Mix to initiate 
amplification. This was followed by 40 cycles comprising of denaturation at 95°C 
for 15 sec and annealing/ extension at 55°C for 1 min. The quantity of the target 
gene was analyzed by ABI Prism®7000 SDS Software {Applied Biosystems). 
2.5.5. Preparation of cDNA standard 
The cDNA standard was generated by PCR amplification of serially 
diluted cDNA plasmids of p-actin or the target gene with known concentrations. The 
cDNA plasmid was prepared as described in section 2.5.6 and quantified by 
spectrophotometry at optical density of 260 nm. The cDNA plasmid was adjusted to 
20 ng/|al in DEPC-treated water. Finally, 10-fold serial dilutions were performed to 
obtain a set of standards ranging from 0.02 pg to 2 ng. 
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2.5.6. Mini-scale preparation of plasmid DNA 
Transformed bacteria were grown in 10 ml of LB Broth (Invitrogen) 
containing 80 |ig/ml ampicillin {Roche) at 2>TC overnight (about 16 hr) with 
shaking at 200 rpm. Bacterial cells were centrifiiged down at 3,000 rpm for 15 min. 
cDNA plasmids were separated from the bacterial DNA by using Rapid Plasmid 
Purification System {Marligen) according to the manufacturer's protocol. In brief, 
for each cell pellet, 250 of Cell Suspension Buffer was added to resuspend the 
cell by vortex. Cells were lysed by mixing with 250 |LI1 of Cell Lysis Solution for 5 
min. The mixture was neutralized by 350 of Neutralization Buffer. The mixture 
was centrifiiged at 14,000 rpm for 10 min. The supernatant was loaded onto a 
cartridge (provided in the kit) and centrifiiged again at 14,000 rpm for 1 min. The 
flow-through was discarded. The cartridge was washed with 700 |ul of Wash Buffer 
and centrifiiged at 14,000 rpm for 2 min. After discarding the flow-through, it was 
centrifbged again at 14,000 rpm for 1 min to eliminate any carryover of the Wash 
Buffer. The plasmid DNA trapped in the cartridge was finally eluted with 100 |il of 
autoclaved water. One )LI1 of extracted plasmid was subjected to electrophoresis in a 
1% agarose gel to confirm the size of the plasmid. Another 1 |iil of plasmid was 
measured by spectrophotometry (GeneQuant, Pharmacia Biotech) at optical density 
of 260 nm for quantification. The rest of the DNA plasmid was kept at -20°C for 
long-term storage. 
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3.1 . INTRODUCTION 
As mentioned in Chapter 1, Cyp26al, which encodes a cytochrome 
P450 enzyme for RA catabolism, is specifically expressed in the tail bud region 
(Fujii et al, 1997). Our laboratory has found that its expression level is significantly 
down-regulated in embryos of diabetic mice (Leung, 2005). Hence, it is envisaged 
that the RA catabolic activity in the tail bud region will be reduced and thus cells in 
the tail bud will be exposed to a higher concentration of RA. To determine if this 
hypothesis is correct, it is important to monitor RA concentrations in the tail bud 
region over a period of time after RA treatment so as to determine the rate of 
removal of the exogenously applied RA. 
The most commonly employed method to detect RA is by high pressure 
liquid chromatography (HPLC). This technique has been used in many studies for 
analyzing RA concentrations in tissues of different organs (Pappas et al.，1993; Kane 
et al, 2005) and embryonic tissues (Maden et al, 1998; Sakhi et al, 1998). Using 
HPLC, the concentration of endogenous a\\-trans RA and a\\-trans retinol in the 
mouse embryo at day 9.5 of gestation was found to be 75.8 pg and 279 pg per 
embryo respectively (Sakhi et al, 1998). However, this level of RA is close to the 
detection limit. A large amount of embryonic tissues is required for HPLC analysis, 
thus making determination of retinoids level in embryos at earlier stages nearly 
impossible. Furthermore, RA is not distributed homogenously throughout the 
embryo. Even within the same organ, it is localized to specific regions. For example, 
in the retina, RA is present in higher levels in the ventral portion than in the dorsal 
part (McCaffery et al., 1992). In the developing central nervous system, there is a 
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RA concentration gradient, with highest levels in the developing spinal cord and 
very low levels in the forebrain (Horton and Maden, 1995). Hence, HPLC is not 
optimal for detailed analysis of the spatial distribution of RA in the embryo. A more 
powerful technique is high pressure liquid chromatography/mass spectrometry 
(HPLC/MS), which has higher sensitivity and specificity for retinoids. In an 
experiment to detect RA level in the retina of the mouse embryo at day 15 of 
gestation by using this technique, about 20.75 pg/fig protein was detected, with 
sensitivity to RA approximately down to 0.7 pmole (McCaffery et al, 2002). 
However, this method is expensive. 
Another method to detect RA is based on bio assay in which RA binds 
to the retinoic acid response element (RARE) that drives the expression of a reporter 
gene. This method is widely employed in the generation of transgenic mice, such as 
RARE-lacZ transgenic mice (Rossant et al, 1991; Balkan et al., 1992; Mic et al., 
2002; Koubova et al, 2005), and RA responsive cell lines (Wagner et al., 1992; 
McCaffery and Drager, 1997; lulianella et al, 1999). The RARE-lacZ mouse is 
commonly used for localizing in situ the distribution of RA in the embryo upon 
staining for p-galactosidase activity to change the substrate X-gal into a colored 
product. For instance, it has been shown that there were distinct temporal and spatial 
distribution patterns of lacZ activity along the anterior-posterior axis (Mendelsohn et 
al, 1991; Balkan et al, 1992). RA responsive cell lines have also been widely used 
for detecting retinoids distribution in the mouse embryo. In a study where tissue 
explants from mouse embryos at day 8.5 and 9.5 of gestation were directly placed on 
top of the RA responsive cells, retinoid bioavailability was found in tissues at the 
posterior so mite-level, but not in the tail bud, suggesting that the tail bud region 
- 3 5 -
Chapter 3: RA Catabolism in Tail Bud 
might contain enzymes for degradation of RA (lulianella et al, 1999). 
Another method to trace endogenous RA in the embryo is by analysis 
of enzymes that mediate RA synthesis and degradation. Study on RA production and 
degradation in the embryonic chick retina has been conducted using the RA 
responsive cell line (Mey et al., 2001). It was found that there was a high level of 
RA synthesizing activity in the retinal pigment epithelium, and in the ventral and 
dorsal poles of the retina, while RA degradation occurred in a horizontal region in 
the middle of the retina. 
Catabolism is important for inactivation of RA. RA can be catabolized 
by a number of pathways that are tissues or species specific. One main route by 
which RA is degraded in the adult liver is via an oxidative pathway involving 
CYP26 enzyme (Robert et al, 1992). CYP26 is a member of cytochrome P450 
family, which can convert oW-trans RA to more polar and oxidized metabolites, such 
as 4 - 0 X 0 , 4-hydroxy and 18-hydroxy RA. In this chapter, I have developed a method 
for determining the RA catabolic activity in a small piece of embryonic tissue (tail 
bud) to degrade RA to a metabolite that could not activate the RARE in a RA 
responsive cell line. 
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3 .2 . EXPERIMENTAL DESIGN 
The aim of this chapter was to determine whether down-regulation of 
Cyp26al in embryos of diabetic pregnancy would reduce the RA catabolic activity 
in the tail bud region of the embryo. To this end, I have employed a RA responsive 
cell line to analyze RA catabolic activity in the tail bud tissue of mouse embryos 
using an in vitro and in vivo approaches. 
The RA responsive cell line was kindly provided by Dr. Peter 
McCaffery. The first part of this chapter was on characterization of this RA 
responsive cell line to achieve the maximum sensitivity and response to RA. 
After characterization, I have established an in vitro assay to compare 
the ability of the tail bud tissue excised from embryos of diabetic and non-diabetic 
mice to degrade a known concentration of RA added to the culture medium. After a 
fixed period of time, the amount of RA remained in the medium was measured by 
the RA responsive cell line. This method was based on established protocols 
(Yamamoto et al. 1998; Mey et al., 2001) with some modifications. 
To fiirther compare the in vivo RA catabolic activity in the tail bud 
region of embryos of diabetic and non-diabetic mice, I have developed a protocol to 
monitor the change in RA levels in the tail bud region in the first 8 hr after maternal 
administration of a teratogenic dose of RA. 
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3.3 . MATERIALS AND METHODS 
3.3.1. Preparation of RA stock solution for cell culture 
All procedures were carried out under sterile condition in a tissue 
culture hood under dim red light. DMSO (Sigma), at a volume of 1.66 ml, was 
added to 50 mg of a\\-trans RA to make a 100 mM stock solution. Aliquots of stock 
solution were kept in brown bottles or microfUge tubes wrapped with aluminum foil 
to avoid photo-oxidation. The stock solution was gassed with nitrogen and then snap 
frozen in liquid nitrogen. It was stored under -80°C and used within 2 months. 
3.3.2. Preparation of RA standard solutions 
The 100 mM RA stock solution was serially diluted to 10"^  M following 
the procedure as indicated in Table 3.1. After that, RA standard solutions from 10"^  
M to 10-15 M were obtained by 10-fold serial dilution with culture medium in a 
stepwise manner to prevent precipitation. 
Table 3.1 Procedures for preparation of RA standard solutions in “normal 
concentration" ofDMSO. 
Final concentration Volume of Volume of Volume of 
ofRA RA solution DMSO culture medium 
10 mM 10)11 of lOOmMRA 90 ii\ -
1 mM 10 III oflOmMRA 90 )li1 -----
500 |iM 50 1^1 of 1 mM RA —— 50 fil 
lO^M(lO'^M)* 20 )Lil of 500 i^M RA - 9 8 0 
1 - 10-15 M 10-fold serial dilution with culture medium 
* RA solution in 1% DMSO 
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3.3.3. Characterization of RA responsive cell line 
3.3.3.1 Determining optimal culture time for maximum response 
To determine the optimal culture time for the RA responsive cell to 
give the highest activity of p-galactosidase, serially diluted RA standard solutions 
from 10-5 M to 10_i5 M, at a volume of 80 fil, were tested in triplicate to the RA 
responsive cells growing on the 96-well plate (refer to sections 2.4.1 and 2.4.2 for 
preparation of 96-well plate). Cells were cultured in the RA standard solutions for 
various duration, from 5 to 30 hr at 5-hr interval, in a 5% CO2 incubator at 37°C. At 
the end of culture, cells were stained with X-gal for detection of p-galactosidase 
activity (refer to section 2.4.3 for staining procedures). 
3.3.3.2 Testing toxicity of DMSO 
Since RA standard solutions were prepared in DMSO, it was necessary 
to determine the toxicity of DMSO to the RA responsive cell. A second set of RA 
standard solutions containing 100-fold higher concentrations of DMSO was 
prepared as indicated in Table 3.2. 
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Table 3.2 Procedures for preparation of RA standard solutions in "100-fold 
higher concentration" of DMSO. 
Final concentration Volume of Volume of Volume of 
of RA RA solution DMSO culture medium 
10 mM lOjil of lOOmMRA 90 |il -----
1 mM 10 i^l of lOmMRA 90 -—— 
500 50 |Lil of 1 mM RA 50 [i\ -
10|iM(10"^M)* 20 III of 500 _ R A 980)^ 1 -----
10"^  M 50 of 10 ^ iM RA ----- 450 ^ il 
10-7 - 10-12 M 10-fold serial dilution with culture medium 
* RA solution in 100% DMSO 
C 1 , 
Serially diluted RA standard solutions from 10" M to 10' M in 
normal and 100-fold higher concentrations of DMSO, at a volume of 80 were 
tested in triplicate to the RA responsive cells growing on the 96-well plate in a 5% 
CO2 incubator at 37°C for 25 hr (optimal culture time for maximum response based 
on results in section 3.4.1.1). At the end of culture, cells were stained with X-gal for 
detection of p-galactosidase activity. 
3.3.3.3 Detection of P-galactosidase activity by P-gal Assay Kit 
Besides using the X-gal staining assay on attached cells, another 
method based on the detection of P-galactosidase activity in lysed cells by the P-gal 
Assay Kit (Sigma) was employed for comparison of detection efficiency. 
Serially diluted RA standard solutions from 10"^  M to M in 
normal concentration of DMSO, at a volume of 80 yd, were tested in triplicate to the 
RA responsive cells growing on the 96-well plate in a 5% CO2 incubator at 37°C for 
25 hr. At the end of culture, cells were stained with either the X-gal staining assay 
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method as described in section 2.4.3 or the P-gal Assay Kit according to the 
manufacturer's instruction. 
In brief, the 96-well plate with RA responsive cells growing on it was 
washed twice with 100 \i\ of PBS per well, aspirated and then air dried. Ten 
micro litres of lysis buffer (provided in the kit) was added to each well. The cell 
underwent freeze-and-thaw, by placing the plate on dry ice followed by a water bath 
at 37°C for 1-2 min in each step, for 5 times to accelerate the lysing process. After 
lysis, 50 |il of cleavage buffer (provided in the kit, added with 0.0027% 
P-mercaptoethano 1) and 20 |il of ortho-nitrophenyl-P-D-galactopyranoside (ONPQ 
provided in the kit) were added to each well. The plate was incubated at 37°C for 30 
min to allow colour development. At the end of the reaction, 25 |il of stop buffer 
(provided in the kit) was added to each well. The level of transcriptional activation 
of the jS-galactosidase reporter gene was quantified as colorimetric readings by an 
ELISA plate reader (SpectraMax 25, Biomolecular Device) at wavelength of 420 
nm. 
3.3.4. In vitro assay of enzymatic degradation of RA 
3.3.4.1 Testing toxicity of enzyme cofactor-reducing agent 
A stock solution containing enzyme cofactor [1.6 mg/ml 
jS-nicotinamide adenine dinucleotide phosphate hydrate (NADPH, Sigma)] and 
reducing agent [0.3 mg/ml dithiothreitol (DTT, Sigma)] was subject to 3-fold serial 
dilution with DMEM to result in working concentrations ranging from 1/3 to 1/243 
of the stock solution. RA responsive cells growing on the 96-well plate were 
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incubated with 80 |il per well of solution containing 50 nM RA and different 
concentrations of enzyme cofactor-reducing agent in a 5% CO2 incubator at 37°C for 
25 hr. At the end of culture, cell growth, assessed in terms of cell density and cell 
death, was determined. Cells were quantified for P-galactosidase activity with the 
X-gal staining assay to determine the sensitivity of the cell line to RA in the 
presence of different concentrations of NADPH-DTT. The experiment was 
conducted in triplicate. 
3.3.4.2 Collection of tail bud 
Embryos from diabetic and non-diabetic mice at day 9.0 of gestation 
were dissected out in LI 5 medium (Gibco) in darkened room under dim red light. 
The body was bisected in the presomitc region at a level one-somite length caudal to 
the last somite. The caudal part was defined as the tail bud of the embryo. To 
minimize differences in the size of the excised tail bud, only embryos at 20-22 
somite-stage were used for experiments. The tail bud was washed with LI5 medium 
and transferred to DMEM. Four tail buds, collected in 5 |il of DMEM, were 
transferred to a microflige tube. The tail buds were lysed by triturating with a 10 |il 
pipette tip, followed by freezing in liquid nitrogen and thawing in a water bath at 
37°C for 1 min in each step and repeated for 5 times. 
Intact tail buds were used as control to determine whether lysis was 
required or not for in vitro degradation of RA. 
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3.3.4.3 In vitro enzymatic reaction 
Intact or lysed tail bud sample in a micro fug e tube was incubated in 50 
of reaction mixture containing 1.6 mg/ml NADPH, 0.3 mg/ml DTT and 50 nM 
aW-trans RA. Incubation was carried out in a 5% CO2 incubator at 37°C for 2 hr, 
protected from light, during which the exogenous RA in the medium was degraded 
by the RA catabolizing enzyme in the tail bud sample. As a negative control, in one 
group, no tail bud sample was added (Blank). 
To test if degradation of RA was mediated via a cytochrome P450 
enzyme, in one group, 10 jiM ketoconazole (1 |il of 500 |iM stock solution in 
DMEM, Sigma), a cytochrome P450 inhibitor, was included in the reaction mixture. 
To further determine if the cytochrome P450 enzyme was CYP26, in another group, 
the reaction mixture contained 100 nM R115866 (1 \i\ of 5 fiM stock solution in 
DMEM, a gift from Johnson and Johnson), a highly potent CYP26 specific inhibitor 
(Stoppie et al. 2000). 
After incubation, based on results in section 3.4.2.1, the reaction 
mixture was diluted 30-fold with DMEM to minimize the toxic effect of NADPH 
and DTT. The diluted reaction mixture, at a volume of 80 i^ l, was tested in 
triplicate to the RA responsive cell growing on the 96-well plate. After incubation in 
a 5% CO2 incubator at 37°C for 25 hr, P-galactosidase activity was analyzed by 
X-gal staining assay (refer to section 2.4.3). A set of serially diluted RA standard 
solutions (refer to section 3.3.2) was tested, in duplicate, to each 96-well plate to 
prepare a standard curve for quantification of RA remained in the reaction mixture. 
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The experiment was conducted in triplicate. 
3.3.5. In vivo assay of enzymatic degradation of RA 
To compare the in vivo RA catabolizing activity of the tail bud of 
embryos from diabetic and non-diabetic mice, after administration of an exogenous 
dose of RA into the pregnant mouse, the tail bud of the embryo was excised at 
various time points and put into the culture medium to allow the release of RA. The 
RA containing medium was then applied to the RA responsive cell line to quantify 
the amount of RA released from the tail bud. 
3.3.5.1 Determining the optimal time for maximum release of RA from the 
tail bud into the medium 
As a pre-requisite for the experiment, it was necessary to determine the 
time required for maximum release of RA from the tail bud into the medium. To this 
end, on day 9.0 of gestation, 50 mg/kg of RA was injected into the non-diabetic 
mouse. After 3 hr [the time at which peak level of RA should have accumulated in 
the embryo, Satre and Kochhar (1989)], the tail bud was excised from the embryo, 
washed 3 times with LI5 medium and individually put into 300 |il of DMEM 
medium in a microflige tube with lid opened. The tail bud was cultured in the 
medium in a CO2 incubator at 37°C for different length of time from 5 to 30 hr. At 
the end of culture, the medium, at a volume of 80 per well, was tested in triplicate 
to the RA responsive cells growing on the 96-well plate. After incubation in a 5% 
CO2 incubator at 37°C for 25 hr, j8-galactosidase activity was analyzed by X-gal 
staining assay (refer to section 2.4.3). A set of serially diluted RA standard solutions 
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(refer to section 3.3.2) was tested, in duplicate, to each 96-well plate to prepare a 
standard curve for quantification of RA that had released from the tail bud into the 
medium. The experiment was conducted in duplicate. 
3.3.5.2 Monitoring of RA remaining in the tail bud after injection of 
exogenous RA 
On day 9.0 of gestation, diabetic and non-diabetic pregnant mice were 
intraperitoneally injected with 50 mg/kg of RA. Embryos were dissected out at 1-hr 
interval until the hr. The tail bud was excised and individually incubated in 
DMEM medium, as described in section 3.3.5.1. Based on the result in section 
3.4.3.1，the tail bud was cultured in the medium for 25 hr for maximum release of 
RA. The medium could be temporarily stored in -80°C, but no more than 3 days. 
The amount of RA in the medium was measured using the RA-responsive cell line 
as described in section 3.3.5.1. The experiment was conducted in triplicate. 
3.3.6. Statistical analysis 
All statistical analyses between groups were compared by Independent 
sample t test using SPSS software {SPSS), with statistical significance level set at p 
value < 0.05. Variance of the data sets was determined by Levene's test. 
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3 .4 . RESULTS 
3.4.1 Optimization of RA responsive cell line 
Before the RA responsive cell line was employed for comparison of 
the RA catabolic activity in the tail bud of embryos of diabetic and non-diabetic 
mice, a series of experiments was conducted to optimize the condition for achieving 
highest sensitivity by the RA responsive cell line. 
3.4.1.1 Effect of incubation time with RA on P-galactosidase expression 
level 
After the RA responsive cell line is exposed to RA, it will take time for 
induction of p-galactosidase expression. Hence, to determine the optimal culture 
time for RA responsive cells to give the highest activity of p-galactosidase, cells 
were exposed to serially diluted RA standard solutions (from to 1 f o r 
various length of time (from 5 to 30 hr). Results were summarized in Graph 3.1. An 
example of staining intensities of RA responsive cells in response to different 
concentrations of RA was shown in Fig. 3.1. As a general trend, RA responsive cells 
showed response and expressed p-galactosidase when exposed to RA at 
concentrations in the range of ICT� to 1 M . Starting from 10''^ M, the higher the 
concentration of RA, the higher the signal intensity (optical density, OD, at 
wavelength of 650 nm), reaching a maximum response at the concentration of 10'^  
M. However, further increase in RA concentrations to 10"^  M and 1 M resulted in 
a decrease in signal intensity. In plotting the linear regression line, a linear 
relationship between log RA concentration and signal intensity was found in the 
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range of to 10'^  M of RA. Hence for all subsequent experiments, a standard 
curve was prepared for RA concentrations within this range only. Moreover, other 
than 10_7，10'8，10"^  10"'° M, two more concentrations lO'^ "^  and lO"^ "^  were also 
used). An example of linear regression line as a standard curve for calculating the 
concentration of RA in the sample was plotted in Graph 3.2 with R = 0.9965. 
Regarding the effect of exposure time, when the RA responsive cells 
were incubated with RA for 5 hr, only a weak response could be detected even at the 
optimal RA concentration of The response increased dramatically by nearly 
3-fold as the incubation time doubled to 10 hr. Increasing incubation time to 15, 20 
and 25 hr caused fiirther enhancement of the response. The highest amount of 
p-galactosidase activity was observed at 25 hr and there was a linear relationship 
between the signal intensity and RA concentrations from M to 10"^  M. 
Prolonged culture to 30 hr caused a dramatic decrease in signal intensity, with the 
level similar to that in cells exposed to RA for 20 hr. This might be due to cell death 
caused by high cell density, or gradual down-regulation or loss of activity of 
p-galactosidase. 
3.4.1.2 Toxicity of RA and DMSO 
In the previous section, it was shown that the expression of 
P-galactosidase reached a peak level at 10'^  M of RA. Further increase in RA 
concentrations resulted in a decrease in p-galactosidase activity. To determine if it 
was related with the toxic effect of high concentrations of RA and/or DMSO, cells 
were incubated with serially diluted RA standard solutions in normal or 100-fold 
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higher concentration of DMSO (refer to Tables 1 and 2 for preparation of RA 
standard solutions). Results were summarized in Graph 3.3. When the concentration 
of DMSO was 0.1% or below (RA standard solutions at 10"^  - M), the level of 
p-galactosidase expressed by cells that had been exposed to the same concentration 
of RA in normal or higher DMSO concentration showed no differences. The toxic 
effect of DMSO began to appear when its concentration reached 1%, with the signal 
intensity decreased by about 50% (compare signal intensity at 10'^  M of RA in 
normal and higher DMSO concentrations). Moreover, when cells were exposed to 
of RA in 0.1% DMSO, P-galactosidase activity was reduced, suggesting that 
the toxic effect of RA began when its concentration was 10"^  M or higher. 
3.4.1.3 Comparison of X-gal staining assay and p-gal Assay Kit for 
detection of p-galactosidase expression 
The X-gal staining assay of p-galactosidase expression is based on the 
detection of colour intensity of stained cells attached on the 96-well plate. The 
sensitivity of this type of assay depends on cell distribution and density on the well. 
Hence, another method based on the use of the P-gal Assay Kit to detect staining 
intensity in “lysed，’ cells was employed for comparison of detection efficiency. 
Results were shown in Graph 3.4. These two detection methods for P-galactosidase 
showed highly similar trends in response to RA at all tested concentrations, thus 
supporting the sensitivity of X-gal staining assay. As X-gal staining assay was 
simpler and much cheaper in running, this detection method was employed for all 
subsequent experiments. 
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3.4.2. In vitro assay of RA catabolic activity in the tail bud 
To determine if there was a reduction in RA catabolic activity in the tail 
bud of embryos from diabetic mice, an in vitro assay was developed, with the 
experimental set-up summarized in Fig. 3.2. In brief, the tail bud of embryos from 
diabetic and non-diabetic mice at day 9.0 of gestation was excised and put into 
DMEM medium containing a known concentration (50 nM) of oW-trans RA and 
enzyme co factor-reducing agent. The RA catabolizing enzyme in the tail bud would 
degrade the exogenous RA in the medium. After a fixed period of incubation, the 
amount of RA remained in the medium was analyzed by the RA responsive cell line. 
3.4.2.1 Toxicity of enzyme cofactor-reducing agent 
CYP26, as a cytochrome P450 enzyme, requires NADPH as cofactor 
and DTT as reducing agent for its functional activity. In a preliminary study, when 
NADPH and DTT were used at concentrations (1.6 mg/ml NADPH, 0.3 mg/ml DTT) 
following some published protocols (Yamamoto et al” 1998), they were found to be 
highly toxic to the RA responsive cells and caused total cell death (Fig. 3.3A and 
3.3B). Hence, an experiment was conducted to find out the minimal dilution factor 
for NADPH and DTT without causing cell toxicity. 
Cells were incubated with 50 nm of RA in the presence of 3-fold to 
243-fold diluted NADPH-DTT. At 3-fold dilution, the concentration of 
NADPH-DTT was still highly toxic to the cell, with majority of cells being dead 
after 25 hr of culture (Fig. 3.3C and 3.3D). Hence, resulting in a low level of 
p-galactosidase expression, with sensitivity of the cell line to RA reduced to less 
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than 15% (Fig. 3.31). At 9-fold dilution, the toxicity of NADPH-DTT was very much 
reduced. There were very few dead cells, but cells were still growing slower than 
normal, reaching only 80% confluence after 25 hr of culture (Fig. 3.3E and 3.3F). 
The sensitivity of the cell line to RA was raised to about 50% (Fig. 3.71). At 27-fold 
dilution or more, no toxicity of NADPH-DTT was observed and cells reached 100% 
confluence after 25 hr of culture (Fig. 3.3G and 3.3H). The sensitivity of the cell line 
to RA became stabilized (Fig. 3.31). 
3.4.2.2 RA catabolic activity in lysed and intact tail buds 
Before comparing the RA catabolic activity in the tail bud of embryos 
of diabetic and non-diabetic mice, an experiment was conducted to determine if lysis 
of the tail bud was required for releasing the enzyme in the tail bud to catabolize RA 
in the medium. Results were shown in Graph 3.5. 
In the negative control with medium containing 50 nM of RA and no 
tail bud tissue (blank), after 2 hr of incubation at 37°C, only 80% of RA was 
detectable in the medium, showing that there was a 20% loss probably due to natural 
degradation. When the tail bud sample (lysed or intact) was added to the 
RA-containing medium in the presence of cytochrome P450 enzyme co factor and 
reducing agent, there was significant reduction in the amount of RA detected in the 
medium {p < 0.001，Tail bud lysate vs. Blank; p < 0.05, Intact tail bud vs. Blank), 
suggesting that RA was degraded by the tail bud sample. In comparing the RA 
degrading activity, the tail bud lysate caused nearly complete degradation of RA, 
with only 5% of RA detectable in the medium after 2 hr of incubation, which was 
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significantly less than the 65% of RA detectable in the intact tail bud sample ip < 
0.001，Tail bud lysate vs. Intact tail bud). Hence, showing that lysis of the tail bud 
was required for efficient degradation of RA in the medium. Tail bud lysate was 
therefore used in all subsequent experiments. 
3.4.2.3 Effect of enzyme cofactor and inhibitor 
Results were shown in Graph 3.6. In the blank control without tail bud 
lysate, 15% of RA in the medium was degraded after 2 hr in culture，which 
represented the basal level of natural degradation. In the presence of cytochrome 
P450 enzyme cofactor and reducing reagent, the tail bud lysate could effectively 
degrade RA in the medium (p < 0.001 vs. Blank), such that only 30% of RA was 
detected in the medium at 2 hr after culture. However, in the absence of enzyme 
cofactor and reducing agent, the RA degrading activity of the tail bud lysate was 
siginificantly reduced {p < 0.001 vs. Tail bud lysate added with NADPH-DTT). 
Furthermore, when a cytochrome P450 inhibitor (ketoconazole) or a CYP26 specific 
inhibitor (R115866) was added, the % of RA being degraded returned to the basal 
level of natural degradation, indicating that the RA degrading activity in the tail bud 
lysate was completely inhibited. Taken together, results showed that the tail bud 
lysate catabolically degraded RA in the medium via a CYP26 enzyme. 
3.4.2.4 Comparsion of in vitro RA catabolic activity of diabetic and 
non-diabetic groups 
Results were shown in Graph 3.7. In the presence of cytochrome P450 
enzyme cofactor and reducing agent, the tail bud tissue of embryos of both diabetic 
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and non-diabetic groups could effectively degrade RA in the medium {p < 0.001 vs. 
Blank). However, the % of RA remaining in the medium in the diabetic group was 
almost doubled of that in the non-diabetic group, showing that the RA degrading 
activity of the diabetic group was significantly less than that of the non-diabetic 
group ip < 0.001). When the CYP26 specific inhibitor R115866 was added, there 
was complete inhibition of the RA degrading activity in both diabetic and 
non-diabetic groups, with the % of RA being detected in the medium the same as the 
blank control, thus providing evidence that the difference in the % of RA being 
detected in the medium between diabetic and non-diabetic groups was due to RA 
catabolic activity in the tail bud lysate mediated via a CYP26 enzyme. 
3.4.3. In vivo assay of RA catabolic activity in the tail bud 
To compare the activity of the tail bud of embryos of diabetic and 
non-diabetic mice to catabolically degrade RA in utew, an in vivo assay was 
developed, with experimental set-up summarized in Fig. 3.4. In brief, after 
administration of an exogenous dose of RA into the pregnant mouse, the amount of 
RA remained in the tail bud over a period of time was determined. This was 
achieved by collecting the tail bud at regular intervals after RA treatment and putting 
in into the culture medium to allow the release of RA. The RA containing medium 
was then applied to the RA responsive cell line to quantify the amount of RA 
released from the tail bud. 
- 5 2 -
Chapter 3: RA Catabolism in Tail Bud 
3.4.3.1 Optimal time for maximum release of RA from the tail bud into the 
medium 
To determine the optimal time for maximum release of RA from the tail 
bud into the medium, individual tail bud of embryos, taken at 3 hr after maternal 
exposure to 50 mg/kg of RA, was incubated in the medium for 5 to 30 hr. Results 
were shown in Graph 3.8. At 5 hr, about 1.5 nM of RA had released from the tail bud 
into the medium. As the incubation time increased, there was a gradual increase in 
the amount of RA being released into the medium, reaching a plateau of 3 nM at 25 
hr. Beyond this incubation time, the RA concentration in the medium dropped 
rapidly by about one-third within 5 hr, possibly as a result of natural degradation. 
3.4.3.2 Comparison of RA remaining in the tail bud of embryos of diabetic 
and non-diabetic mice 
After establishing the in vivo assay to determine RA level in the tail 
bud in 3.4.3.1，the amount of RA remained in the tail bud of embryos of diabetic and 
non-diabetic mice at various time points after maternal RA treatment was compared. 
Results were shown in Graph 3.9. As a general trend, in both non-diabetic and 
diabetic pregnancies, after maternally treated with an exogenous dose of RA, RA 
was rapidly taken up by the embryo and reached a maximum level in the tail bud by 
3 hr. Afterwards, the amount of RA in the tail bud rapidly decreased and by 8 hr, 
most of the exogenous RA had been removed to a level that could no longer be 
detected by the RA responsive cell line. 
When comparing the amount of RA remained in the tail bud of 
embryos in non-diabetic and diabetic pregnancies, there were significant differences 
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between these 2 groups from 1 to 7 hr (/? < 0.001 ND vs. SD at the same time point. 
Table 3.3). Hence, the effective concentration of RA in the tail bud of the diabetic 
group, measured in terms of area-under-curve over the 8 hr period, was doubled the 
amount in that of the non-diabetic group. 
Table 3.3 Statistical analysis on the amount of RA released from the tail 
bud tissue of diabetic and non-diabetic groups at different time 
points after maternal RA treatment. 
Time “ “ , , . RA released No. of No. of p value of after RA Group from tail bud ^ litters embryos ND vs. SD injection (nM) 士 SE 
1 hr ND 5 40 1.570 土 0.094 <0.001* 
SD 5 32 2.170±0.111 
2hr ND 6 33 3.430 ±0.152 <0.001* 
SD 6 31 5.254 土 0.217 
3hr ND 5 36 4.209 土 0.130 <0.001* 
SD 8 42 6.705 ±0.201 
4hr ND 5 31 1.936 士 0.08 <0.001* 
SD 7 33 5.638 士 0.226 
5hr ND 7 38 1.189 ±0.060 <0.001* 
SD 7 37 3.525 土 0.138 
6hr ND 6 38 0.274 ±0.021 <0.001* 
SD 7 41 1.921 土 0.089 
7hr ND 5 34 0.066 士 0.005 <0.001* 
SD 4 25 0.485 士 0.076 
8hr ND 3 16 0.000 =0.178 
SD 3 n 0.001 
ND: Non-diabetic 
SD: Diabetic 
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3 .5 . DISCUSSION 
In this chapter, first I have made a detailed characterization of the RA 
responsive cell line for achieving maximum sensitivity to RA. Regarding the 
response of the cell line to RA, the longer the incubation time, the higher the 
expression level of p-galactosidase, reaching a peak level at 25 hr of incubation 
(Graph 3.1). This finding suggests that it takes time for transcriptional activation and 
translation of the P-galactosidase reporter gene. However, prolonged incubation 
beyond 25 hr resulted in a decrease in the quantity of P-galactosidase. This was 
probably due to cell death caused by over growth of the cells, as cells already 
reached confluence by 25 hr. Results of this study also showed that this cell line has 
sensitivity to RA down to 10"'® M. Within the concentration of 10"^  M to M, 
there was a linear relationship between the signal intensity and the concentration RA. 
On the other hand, concentration of RA at 1 M or higher was already toxic to the 
cell. Thus, this cell line was very useful for detection of low concentrations of RA. 
After characterization, the RA responsive cell line was used for a series 
of in vitro and in vivo assays. In the in vitro assay, it was found that enzyme cofactor 
NADPH and reducing agent DTT used at concentrations necessary for in vitro 
enzymatic degradation of RA by the tail bud tissue was highly toxic to the RA 
responsive cell line. To overcome this problem, after enzymatic reaction, the 
medium containing NADPH-DTT was diluted 30-fold before adding to the RA 
responsive cells for the detection of RA concentration. At such dilution, there was 
normal cell growth and expression of P-galactosidase (Fig. 3.3). 
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Degradation of RA in the medium was observed after addition of tail 
bud tissue (either lysed or intact) in the presence of enzyme cofactor and reducing 
agent, suggesting that the tail bud region of the embryo contained enzymes with RA 
catabolic activity. However, although intact tail bud could degrade RA in the 
medium, the activity was very much lower in comparison to lysed tail bud (Graph 
3.5). It was probably because lysis allowed the release of the RA degrading enzyme 
from the cytoplasm of the tail bud cell into the medium to achieve efficient 
enzymatic reaction in degrading the RA. 
However, when NADPH and DTT (cofactor and reducing agent for the 
cytochrome P450 enzyme) was not added to the medium, the RA degrading activity 
of the tail bud lysate was dramatically reduced (Graph 3.6), suggesting that RA 
degradation by the tail bud tissue was mediated via a NADPH-dependent 
cytochrome P450 enzyme. Further evidence was provided by the finding that 
addition of a cytochrome P450 enzyme inhibitor ketoconazole completely inhibited 
the RA degrading activity in the tail bud tissue. Moreover, as mentioned, CYP26 is a 
member of cytochrome P450 enzyme family responsible for RA degradation (Ray et 
al., 1997), and Cyp26al, one of the subtype of Cyp26 genes, was expressed in the 
tail region during embryo development (Sakai et al, 2001; Leung, 2005). Thus, 
when a CYP26 specific inhibitor (R115866) was added to the culture medium, a 
100-fold concentration less than that of ketoconazole was already sufficient to cause 
total inhibition of the reaction. Taken together, it can be concluded that RA 
degradation in the tail bud was mediated specifically via a CYP26 enzyme. Thus, the 
finding that the RA degrading activity in the tail bud of the diabetic group was 
significantly less than that in the non-diabetic group (Graph 3.7) was in agreement 
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with results of our previous study that the Cyp26al expression level was 
significantly down-regulated in the tail bud region of embryos under diabetic 
pregnancy (Leung, 2005). 
Other than d\\-trans RA, the RA responsive cell line used in this 
study has also been demonstrated to show weak responses to different RA 
derivatives such as 4-oxo, 13-demethyl and 9-cis RA (Yamamoto et al, 1998). 
However, the responsiveness of the cell line to these derivatives is about 20-fold less 
than that to dX\-trans RA. In the in vitro assay testing the RA catabolic activity in the 
tail bud, 4 - 0 X 0 RA was one of the breakdown products of oW-trans RA. However, 
since the concentration of dX\-trans RA in the medium was only 50 nM, even when 
100% of it was degraded, the amount of 4-oxo RA thus formed would be far below 
the detection limit of the cell line. 
After confirming by in vitro assay that the tail bud of embryos of 
diabetic mice had reduced RA catabolizing activity, the ability of the tail bud to 
catabolically remove in vivo a teratogenic dose of RA was compared between 
embryos of diabetic and non-diabetic mice. To do so, I have established a protocol to 
monitor the amount of RA remained in the tail bud over a period of time after 
maternal injection of RA. The amount of RA remained in the tail bud was assessed 
in terms of the amount of RA released into the medium. Results showed that it took 
20 to 25 hr for the release of maximum amount of RA into the medium (Graph 3.8). 
However, the amount of RA in the medium was a balance between the rate of 
diffusion of RA from the tail bud into the medium and the rate of natural degradation. 
Thus in prolonged incubation beyond 25 hr, less RA was detected, probably because 
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most of the RA in the tail bud had already diffused out, but degradation continued. 
As shown in Graph 3.9, after maternal RA treatment, the level of RA in the tail bud 
increased rapidly at the first 3 hr, followed by a rapid decrease in subsequent hours, 
and already returned to basal level by 8 hr. This result was consistent with the 
finding by lulianella et al. (1999), which showed that a high concentration of RA 
accumulated in the tail bud of mouse embryos at 3 hr after maternal treatment with 
100 mg/kg of RA on day 8.5 of gestation, but the RA content rapidly dropped by 6 
hr. As mentioned, Cyp26al has two RAREs and its expression can be regulated by 
RA (Ray et al.，1997; lulianella et al, 1999; Loudig et al, 2000; Loudig et al., 2005). 
Increase in RA concentration in the tail bud region after treatment with exogenous 
RA will likely up-regulate Cyp26al expression. Such up-regulation of Cyp26al may 
increase the activity in removing the exogenous RA accumulated in the tail bud and 
thus leads to rapid removal of RA within several hours. However, since RA catabolic 
activity in the tail bud of embryos of diabetic pregnancy is significantly less than 
that in non-diabetic pregnancy, this will lead to a higher effective concentration of 
RA in the tail bud region (Graph 3.9) and may thus account for the increased 
susceptibility to RA-induced caudal regression as previously reported by our 
laboratory (Shum et al., 2002). To examine the above hypothesis, changes in the 
expression level of Cyp26al in the tail bud region at different time points after 
maternal RA treatment were compared between embryos of diabetic and 
non-diabetic mice in the next chapter. 
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4.1 . INTRODUCTION 
As mentioned in section 1.5.3，RA catabolism is controlled by Cyp26 
of the cytochrome P450 enzymes family. Indeed, there are 3 subtypes of Cyp26 
genes. Chapter 1 described the well-studied one, Cyp26al. The other two subtypes 
are Cyp26bl and Cyp26cl. All three Cyp26 genes are required for establishing an 
uneven distribution of RA along the anterio-posterior axis and for maintaining a low 
RA concentration for particular organ development during embryogenesis. For 
example, Cyp26al is important for posterior development (Abu-Abed et al., 2001; 
Sakai et al., 2001) while Cyp26bl is responsible for gonad development and sex 
determination (Koubova et al., 2006). 
The second subtype of Cyp26, Cyp26bl’ was first identified in humans 
(Nelson, 1999). It was found predominantly expressed in adult cerebellum and 
showed high efficiency of catabolism and substrate specificity to a\\-trans RA 
(White et al., 2000). Similar to Cyp26al, cells transiently transfected with Cyp26bl 
could convert dX\-trans RA to more polar metabolites including 4-oxo, 4-hydroxy 
and 18-hydroxy RA. The mouse ortholog of Cyp26bl has also been cloned and 
characterized by MacLean et al. (2001). 
The third subtype of Cyp26, Cyp26cl, has also been cloned. Sequence 
analysis shows that Cyp26cl is more closely related to Cyp26bl than Cyp26al. 
However, CYP26C1 appears to have slightly different enzymatic properties 
(Tahayato et al., 2003; Taimi et al., 2004). Analysis of CYP26C1 activity in vitro 
shows that other than metabolizing a\\-trans RA, it can also hydrolyze 9-cis RA with 
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a much greater efficiency than either CYP26A1 or CYP26B1 (Taimi et al., 2004). 
The three Cyp26 genes exhibit different expression patterns during 
embryo development, indicating that they may be responsible for protecting 
different tissues from inappropriate RA signaling. As previously mentioned, mouse 
Cyp26a 1 expression is highly restricted to the tail bud and cervical mesenchyme 
(Fujii et al., 1997; MacLean et al., 2001). In contrast, Cyp26bl is more widely 
expressed in the embryo than Cyp26a 1 and Cyp26c], with transcripts being present 
in the hindbrain from day 8.0 to day 10.5 of gestation, and in the developing limb 
bud, branchial arches, craniofacial structures and various organs in later stages 
(MacLean et al.，2001; Abu-Abed et al., 2002). Recent studies show that Cyp26bl is 
responsible for sex determination, with Cyp26bl being completely turned off in the 
embryonic ovary, but highly expressed in the embryonic testis (Koubova et al., 
2006). Cyp26bl maintains RA in low levels in the developing testis that blocks 
meiosis and acts as a survival factor to prevent apoptosis of male germ cells 
(Maclean et al., 2007). Cyp26c 1 is expressed in the hindbrain between day 8.0 and 
day 9.5 of gestation, and also overlaps in some regions with Cyp26a 1, including the 
tooth buds and mandibular-maxillary cleft of the first branchial arch (MacLean et al., 
2001; Tahayato et al., 2003). However, knockdown of Cyp26cl showed no effects 
on embryo development (Uehara et al., 2007). It is possible that the function of 
Cyp26c 1 is totally replaced by Cyp26al, as they may be functionally redundant. 
This is supported by the finding that embryos with homologous disruption of both 
Cyp26a 1 and Cyp26c 1 manifested pronounced anterior truncation of the brain due to 
failure in producing migratory cranial neural crest cells in the forebrain and 
midbrain (Uehara et al., 2007). 
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Many of the tissues that express Cyp26 genes are shown to be sensitive 
to the effect of RA. Common phenotypes of RA teratogenicity include spina bifida, 
caudal regression, limb truncations, cleft palate, hindbrain posteriorization, 
micrognanthia and other craniofacial abnormalities (Eichele, 1989; Conlon and 
Rossant, 1992; Maden and Holder, 1992; Rowe et al., 1992; Shum et al., 1999). Of 
these phenotypes, spina bifida, caudal regression and subtle changes in hindbrain 
patterning are observed in Cyp26al null mice (Abu-Abed et al., 2001; Sakai et al., 
2001). Such abnormalities are also commonly found in infants of diabetic pregnancy 
as previously mentioned in section 1.2. 
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4.2 . EXPERIMENTAL DESIGN 
In Chapter 3, I have shown that RA catabolism in the tail bud region 
was contributed by CYP26. Complete inhibition of RA catabolism could be 
achieved by addition of CYP26 specific inhibitor (R115866) in an in vitro system. 
Furthermore, I found that the RA catabolic activity was decreased under diabetic 
conditions, which was agreeable with our previous results that the expression level 
of Cyp26al in embryos was significantly down-regulated under maternal diabetes. 
However, other than Cyp26al, there are two more subtypes of Cyp26, Cyp26bl and 
Cyp26cl. Many studies have been carried out to investigate the biological functions 
and expression patterns of these two genes, but their responses under diabetic 
conditions are still unknown. 
In this chapter, first, I compared the expression level of the three Cyp26 
subtypes in the tail bud region of embryos in both non-diabetic and diabetic groups 
by real-time quantitative RT-PCR. 
Results in the first part of study showed that Cyp26al was the only 
subtype that showed alteration in expression levels under diabetes. Hence, in the 
second part of this chapter, I focussed on the molecular change of Cyp26al in the 
presence of exogenous RA. The expression level was measured using real-time 
quantitative RT-PCR and results were compared and analyzed with reference to the 
findings in Chapter 3. 
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4.3 . MATERIALS AND METHODS 
4.3.1. Sample collection 
Diabetic or non-diabetic female mice were mated with non-diabetic 
male mice as described in section 2.1. On day 9.0 of gestation, pregnant mice 
received intraperitoneal injection of a single dose of 50 mg/kg body weight of RA or 
equivalent volume of suspension vehicle as control. Pregnant mice were sacrificed 
prior to (0 hr), 2 hr, 4 hr, 8 hr and 12 hr after RA treatment. Embryos were collected 
for real-time quantitative RT-PCR studies. Blood glucose level was measured prior 
to RA injection to ensure that the mouse remained diabetic during pregnancy. 
Embryos at the desired time point were dissected in ice-cold PBS and 
freed from all decidual tissues and extraembryonic membranes. The tail bud (as 
defined in section 3.3.4.2) was collected. As gene expression and the size of the tail 
bud will change with developmental stage, only embryos at specific somite-stage 
(17-19 somite-stage for 0 hr, 19-20 somite-stage for 2 hr, 21-22 somite-stage for 4 hr, 
23-24 somite-stage for 8 hr and 26-27 somite-stage for 12 hr) were collected for 
analysis. Tissues of the same litter were pooled and immediately stored in ^RHAlater 
RNA Stabilization Reagent as described in section 2.5.1. 
4.3.2. Real-time quantitative RT-PCR 
Total RNA extraction of the tail bud sample and first-strand cDNA 
synthesis by RT were performed as described in sections 2.5.2 and 2.5.3 respectively. 
After RT reaction, expression levels of Cyp26al, Cyp26bl and Cyp26cl were 
determined by real-time quantitative PCR. /3-actin was used as the internal control 
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for normalization of PCR products. The PGR conditions were as described in section 
2.5.4. To quantify the amount of Cyp26 and p-actin genes, cDNA standards were 
added in each set of PCR. The standards were prepared as described in section 2.5.5. 
The cDNA plasmids of mouse Cyp26al’ Cyp26bl and Cyp26cl were kindly 
provided by Prof. Hiroshi Hamada. The PCR products amplified were: a 222 bp 
sequence corresponding to nucleotide sequences 504-725 of mouse Cyp26al, a 185 
bp sequence corresponding to nucleotide sequences 2912-3096 of mouse Cyp26bl, a 
152 bp sequence corresponding to nucleotide sequences 719-870 of mouse Cyp26cl, 
and a 165 bp sequence corresponding to nucleotide sequences 304-468 of mouse 
P-actin. The sequences of primers for amplification of partial sequence of the target 
gene were as follow: 
Cyp26al forward primer: 5，-CAG TGC TAC CTG CTC GTG AT-3， 
reverse primer: 5'-AGA GAA GAG ATT GCG GGT CA-3' 
Cyp26bl forward primer: 5，-CCT GGT GAG GAT GAA TAA GG-3’ 
reverse primer: 5，-TTT CCA CCT TAC CTC TCT GC-3' 
Cyp26cl forward primer: 5’-GGG ACC AGT TGT ATG AGC AC-3’ 
reverse primer: 5，-AGC CAA CTC CTT CAG CTC TT-3’ 
P-actin forward primer: 5'-TGT TAC CAA CTG GGA CGA CA-3 ’ 
reverse primer: 5,-GGG GTG TTG AAG GTC TCAAA-3' 
After PCR, expression levels of these genes were analyzed by ABI 
Prism®7000 SDS Software {Applied Biosystems). 
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4.3.3. Statistical analysis 
The relative expression levels of Cyp26 genes between embryos of 
diabetic and non-diabetic mice at different time points with or without RA treatment 
were compared by Independent sample t test. The extent of up-regulation of 
Cyp26al after RA treatment between embryos of diabetic and non-diabetic mice at 
different time points were compared by one-way ANOVA followed by Contrast test. 
All statistical analyses were carried out using SPSS software (SPSS), with statistical 
significance level set at p < 0.05. Variance of the data sets was determined by 
Levene's test. 
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4.4. RESULTS 
4.4.1. Relative expression levels of Cyp26al, Cyp26bl and Cyp26cl 
The relative expression levels of Cyp26al, Cyp26bl and Cyp26cl in 
the tail bud region of embryos in non-diabetic (ND) and diabetic (SD) pregnancies 
at day 9.0 of gestation were summarized in Table 4.1 and presented in Graph 4.1. 
Results showed that the expression level of Cyp26al was significantly 
down-regulated {p < 0.001) in the tail bud region of embryos of the diabetic group 
when compared with that of the non-diabetic group. Expression levels of Cyp26bl 
and Cyp26cl were 15- and 20-fold respectively lower than that of Cyp26aL Both 
Cyp26bl and Cyp26cl expression levels did not show any obvious differences 
between non-diabetic and diabetic groups. 
Table 4.1 Relative expression levels of Cyp26al，Cyp26bl and Cyp26cl in the 
tail bud region of embryos of non-diabetic (ND) and diabetic (SD) 
mice. 
Maternal status ND SD 
No. of litters 5 5 
No. of embryos 35 30 
Relative expression levels of 
0.185 士 0.011 0.126 士 0.006* 
Cyp26al 士 SE 
Relative expression levels of 
0 . 0 1 2 士 0 . 0 0 2 0 . 0 1 2 士 0 . 0 0 2 
Cyp26bl 土 SE Relative expression levels of 0.009 士 0.001 0.010 士 0.000 Cyp26cl 土 SE * Statistically significant from ND 
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4.4.2. Molecular changes in Cyp26al in tail bud region after maternal 
RA treatment 
After confirming that Cyp26al is the subtype predominantly expressed 
in the tail bud region with expression levels being affected in diabetic pregnancy, 
changes in expression levels of Cyp26al at different time points after RA treatment 
were compared between non-diabetic and diabetic groups. Results were summarized 
in Table 4.2 and presented in Graph 4.2. Results of statistical analysis were shown in 
Tables 4.3 and 4.4. 
Without treatment with RA (CON), the expression level of Cyp26al in 
the tail bud region of embryos of diabetic mice was significantly {p < 0.001 to p < 
0.05，ND vs. SD at the same time point) lower than that of embryos of non-diabetic 
groups at all time points studied (Tables 4.2 and 4.3, Graph 4.2). Upon maternal 
treatment with an exogenous dose of RA (RA), there was a gradual and significant 
up-regulation of Cyp26al in the tail bud region of both non-diabetic [p < 0.001，ND 
(CON) vs. ND (RA) at the same time point] and diabetic groups \p < 0.001, SD 
(CON) vs. SD (RA) at the same time point]. The up-regulation was detectable as 
soon as 2 hr after RA treatment and reached a peak level at 8 hr (with a 5-fold 
increase compared to the basal level). The expression level of Cyp26al was rapidly 
reduced by 12 hr. At all time points studied, the up-regulated expression level of 
Cyp26al in the tail bud region of embryos of diabetic mice was significantly lower 
than that of embryos of non-diabetic mice \p < 0.001 to p < 0.05, ND (RA) vs. SD 
(RA) at the same time point]. Moreover, in comparing the extent of up-regulation of 
Cyp26al, embryos of diabetic mice was significantly less than that of embryos of 
non-diabetic mice at 8 hr and 12 hr time point ip < 0.05, analyzed using one-way 
ANOVA followed by Contrast test; Table 4.4). 
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Table 4.2 Relative expression levels of Cyp26al in the tail bud region of embryos of different treatment group 
T r :二n t ND (CON) SD (CON) ND (RA) 
^ ^ of time Ohr 2 hr 4hr 8hr 12 hr Ohr 2hr 4hr 8hr 12 hr 2hr 4 hr 8 hr after RA injection 
No. of litters 5 5 5 5 4 5 5 5 5 4 5 5 5 
No. of embryos 19 23 23 24 18 21 19 23 22 19 20 21 22 
Relative 0.183 0.182 0.207 0.197 0.230 0.130 0.121 0.148 0.136 0.174 0.366 0.571 1.052 丨 
expression levels ± 土 士 士 土 土 士 士 土 士 士 士 士 
of Cyp26al± SE 0.006 0.011 0.009 0.009 0.009 0.006 0.011 0.008 0.008 0.010 0.021 0.035 0.040 
I “ 
Table 4.3 Statistical analysis of relative expression levels of Cyp26al in the tail bud region of embryos o 
groups using Independent sample t test. 
Tr;二T^ ND (CON) vs. SD (CON) ND (CON) vs. ND (RA) SD (CON) vs. SD (RA) 
L e n ^ of time after � h r 2 hr 4 hr 8 hr 12 hr 2 hr 4hr 8hr 12 hr 2hr 4hr 8 hr 12 hr RA injection 
p value in comparing �Q.OOI 0.005 0.001 0.001 0.012 <0.001 <0.001 <0.001 <0.001 <0.001 <0.001 <0.001 <0.00 relative expression * * * * * * 本 * * * * * * 
levels of Cyp26al 
I -J 0 I “ 1 “ “ “ “ “ ^ 
1 
* Statistically significant 
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Table 4.4 Statistical analysis of relative expression levels of Cyp26al in the 
tail bud region of embryos of different treatment groups using 
one-way ANOVA followed by Contrast test. 
Difference between ND (CON) & ND (RA) 
Treatment groups vs. 
Difference between SD (CON) & SD (RA) 
Length of time after RA injection 2 hr 4 hr 8 hr 16 hr 
p value in comparing relative 
0.489 0.301 0.035* 0.008* 
expression levels of Cyp26al 
* Statistically significant 
- 7 1 -
Chapter 4: Molecular Analysis of Cyp26 
4.5 . DISCUSSION 
In this study, it was shown that Cyp26al, being the predominantly 
expressed RA catabolizing enzyme in the tail bud region of the embryo, was 
significantly down-regulated in embryos of diabetic mice. Although there were no 
detectable changes in Cyp26bl and Cyp26cl in the tail bud region of embryos under 
diabetic pregnancy, the possibility that they might be altered in other parts of the 
embryo where they were highly expressed could not be ruled out. Further 
investigation on these two genes is therefore required. Moreover, my preliminary 
data (not shown) indicated that, other than Cyp26al, Cyp26bl could also be 
up-regulated upon RA treatment in the tail bud region of embryos, whereas Cyp26cl 
remained unchanged. These results are in agreement with findings by Reijntjes et al. 
(2005), which showed that exogenous RA could up-regulate expressions of Cyp26al 
and Cyp26bl in the posterior region of chick embryos, while expressions of 
Cyp26cl were unaffected. However, although Cyp26bl could be up-regulated by 
RA, its expression level in the tail bud region was still far lower than the basal 
expression level of Cyp26al without RA treatment, supporting that Cyp26al is the 
main RA catabolizing enzyme in the tail bud region of embryos responsible for 
maintaining RA homeostasis important in proper caudal development. 
The locus of Cyp26al has been shown to contain two RARE, R1 and 
R2 (Loudig et al., 2000; Loudig et al., 2005). Hence, Cyp26al expression can be 
induced by RA through binding to the RAR/RXR heterodimers (refer to section 
1.5.1). The locus of Cyp26bl has not been reported to contain a RARE, even though 
it was found up-regulated upon RA exposure (Reijntjes et al., 2005). Results of this 
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chapter on change of Cyp26al expression levels agree with results in Chapter 3 on 
the effective RA concentrations remaining in the tail bud upon exposure to a 
teratogenic dose of RA (Graph 3.9). After RA injection, exogenous RA has already 
reached the tail bud region of the embryo at the first hour and might in turn 
up-regulate the expression of Cyp26a 1. Indeed, results of this chapter showed that a 
significant up-regulation of Cyp26a 1 was already detectable at 2 hr after RA 
treatment. Further increase in Cyp26a 1 level was accompanied by a rapid decline in 
RA concentrations in the tail bud, probably as a result of catabolic removal by 
CYP26A1. As the RA level dropped, Cyp26al began to down-regulate to basal level. 
Moreover, results of this study also showed that the expression level of Cyp26al in 
embryos of diabetic mice was significantly lower than that in embryos of 
non-diabetic mice with or without RA treatment. This might lead to reduced ability 
in removing exogenous RA and thus consistent with the finding in Chapter 3 that 
there was a higher concentration of RA in the tail bud region, with the 
area-under-curveo-8hr being doubled, in the diabetic group. Such higher RA 
concentrations remained in the tail bud might exert molecular actions, such as 
enhancing down-regulation of WntSa in the tail bud (Shum et al., 1999，refer to 
section 1.6). As a result, the teratogenic effect of RA was increased in embryos of 
diabetic mice in comparison to embryos of non-diabetic mice, leading to a greater 
extent of caudal regression. 
The mechanism for down-regulation of Cyp26al in embryos under 
diabetic pregnancy is still unknown. It may be related to the RA level in the embryo 
as Cyp26al is inducible by RA (Ray et al., 1997). As mentioned in section 1.4， 
plasma vitamin A levels are lowered in humans with type 1 diabetes (Basu and 
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Basualdo, 1997; Olmedilla et al., 1997; Granado et al., 1998; Baena et al., 2002), 
and in streptozotocin-induced diabetic rats (Tuitoek et al, 1996). Since RA in the 
embryo is synthesized from vitamin A obtained from maternal blood circulation, it is 
possible that a lowering of vitamin A levels in the plasma of diabetic mothers can 
lead to reduced RA levels in the embryo. This hypothesis is supported by findings 
from our laboratory that the expression of the key RA synthesizing enzyme, Raldh2, 
was down-regulated in embryos of diabetic pregnancy or cultured under 
hyperglycemic conditions (Leung, 2006), making it possible that RA levels are 
reduced. Taken together, maternal diabetes may alter RA homeostasis and further 
investigation is required. 
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5.1 . INTRODUCTION 
As mentioned in section 1.5, RA is an essential molecule for normal 
embryonic development and its concentration is tightly regulated. To study RA 
homeostasis, various knockout mice of RA synthesizing and degrading enzymes 
were generated (Yamaguchi et al., 1998; Sakai et al., 2001; Martin et al., 2005; 
Maclean et al., 2007). In my project, I have employed Cyp26al knockout mice to 
investigate the association between Cyp26al with diabetic pregnancy. Cyp26a广卜 
mutants appear morphologically normal and are fertile. However, Cyp26ar^~ 
mutants died at mid-gestation or within one day after birth (Abu-Abed et al., 2001). 
Morphological abnormalities first appeared in Cyp26al+ embryos at 
day 9.5 of gestation. Posterior truncation was found in all embryos and 75% of them 
also exhibited exencephaly. Some embryos also manifested additional defects in 
hindbrain, vertebral and limb patterning, irregular folding of the neural tube, 
incomplete axial turning and heart abnormalities (Abu-Abed et al., 2001; Sakai et al., 
2001). Recent studies show that Cyp26al is also responsible for proper head 
development (Ribes et al., 2007). Upon exposure to a low dose of exogenous RA (1 
mg/kg), Cyp26al"- mutants exhibited head truncation, while Cyp26al+" and 
Cyp26a严 embryos appeared normal (Ribes et al., 2007). However, the forelimb 
bud of Cyp26ar'~ embryos were unaffected, showing that the effect of exogenous 
RA on head development might probably be due to a transient increase in RA levels 
(Sakai et al., 2001). 
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Caudal agenesis, one of the major malformations in Cyp26a厂卜 mice, 
is phenotypically similar to that induced by administration of excess RA (Shum et al., 
1999). In both cases, there are disorganized neural tissue outgrowth within the 
truncated tail rudiments. There was an increase in endogenous RA level in the tail 
bud of mutant embryos when compared with that of wild-type embryos (Sakai et al., 
2001). The expression pattern of Raldh2 was not altered in Cyp26al_— embryos. 
However, its RA-containing regions greatly exceeded the regions expressing Raldhl. 
These findings suggest that the presence of Cyp26al is required to prevent the 
diffusion of RA from the RA synthesizing trunk into the tail bud region. Interestingly, 
these abnormalities could be rescued by heterozygous disruption of Raldh2 that 
diminished RA synthesis (Niederreither et al., 2002). Lack of Cyp26al also resulted 
in homeotic transformation of vertebrae as well as misspecification of the rostral 
hindbrain associated with anterior expansion of RA-positive domains (Abu-Abed et 
al., 2001). 
As mentioned in section 1.6，Wnt3a and Brachyury are genes important 
for caudal development. Wnt3a+ and Brachyury—" mutant embryos exhibit caudal 
truncation accompanied by excessive neural tube formation at the expense of 
mesoderm (Wilkinson et al., 1990; Takada et al., 1994; Yoshikawa et al., 1997; 
Yamaguchi et al., 1999). Interestingly, these 2 critical genes were found altered in 
Cyp26a「卜 embryos. The expression of Brachyury in wild-type embryos were 
localized in the caudal streak and notochord at day 9 of gestation (Takada et al., 
1994). In Cyp26al—- embryos, the expression of Brachyury was largely preserved, 
but it always bifurcated in the posterior region (Sakai et al., 2001). Moreover, its 
expressions in the posterior mesoderm and neural plate were significantly 
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down-regulated (Fujii et al., 1997). The expression of WntSa was also decreased in 
the tail bud of Cyp26al+ embryos at day 9 of gestation (Sakai et al., 2001). 
Similarly, expressions of both Wnt3a and Brachyury were down-regulated upon 
administration of exogenous RA (lulianella et al, 1999). Taken together, increase in 
endogenous RA concentrations in Cyp26al+ embryos could down-regulate Wnt3a 
and Brachyury expression in the tail bud, which in turn impaired the proliferation of 
mesodermal cells and transformed mesoderm into neural fates, causing severe axial 
truncation with terminal neural tissues apparent in the mutant. 
To conclude, most of the malformations found in Cyp26al~^~ embryos 
were similar to those caused by excess RA and in diabetic pregnancy. It is therefore 
possible that there is an inverse relationship between the level of Cyp26al 
expression and the level of RA, such that the lower the Cyp26al expression level in 
the tissue, the higher the RA concentration and thus the teratogenicity. 
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5.2 . EXPERIMENTAL DESIGN 
As mentioned in Chapter 1, the expression level of Cyp26al in 
embryos of non-diabetic and diabetic pregnancies was found to be significantly 
different. In Chapter 3, I have shown that concomitant with down-regulation of 
Cyp26al in diabetic conditions, the RA catabolic acitivity mediated via a CYP26 
enzyme was significantly down-regulated in the tail bud region of embryos of 
diabetic mice. I have further shown in Chapter 4 that of the three subtypes of Cyp26, 
only Cyp26al was predominantly expressed in the tail bud region and was 
significantly affected by maternal diabetes. However, it remained to be determined 
whether down-regulation of Cyp26al was directly involved in the increased 
susceptibility to caudal regression in diabetic pregnancy. To this end, I have 
compared, in this chapter, the susceptibility of embryos with haploinsufficiency of 
Cyp26al and their wild-type littermates to RA-induced caudal regression in diabetic 
and non-diabetic pregnancies. To do so, Cyp26al+" male mice were mated with 
non-diabetic or diabetic ICR female mice to produce 4 types of embryos, including 
Cyp26a广+ embryos in non-diabetic pregnancy (ND+〜，Cyp26a广-embryos in 
non-diabetic pregnancy Cyp26a严 embryos in diabetic pregnancy (SD+汗） 
and Cyp26al+ embryos in diabetic pregnancy (SD+"). The aim of this chapter was 
to decipher the relationship of maternal diabetes, Cyp26al expression levels and RA 
catabolic activity in the tail bud region in affecting the embryo's susceptibility to 
caudal regression. 
First, the expression level of Cyp26al in the tail bud region of embryos 
in the 4 groups as mentioned above was measured by real-time quantitative RT-PCR. 
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This was to determine whether a direct relationship existed between maternal 
diabetes and Cyp26al expression levels. 
Secondly, to determine whether differences in Cyp26al expression 
levels would affect the RA catabolic activity, the amount of RA remaining in the tail 
bud region of embryos of different groups at 3 hr after maternal treatment with 25 
mg/kg or 50 mg/kg of RA was compared. Two different dosages of RA were used in 
order to monitor the change in RA catabolism upon different RA teratogenicity. 
Analysis was conducted at 3 hr after RA treatment because based on results in 
section 3.4.3.2 (Graph 3.9)，at this time point, peak RA levels were detected in the 
tail bud region of embryos with significant differences observed between 
non-diabetic and diabetic groups. 
Finally, the extent of RA-induced caudal regression was compared 
among embryos of the 4 groups to determine if there was any correlation with 
Cyp26al expression levels and RA catabolic activity in the tail bud. 
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5.3. MATERIALS AND METHODS 
5.3.1. Animal 
Female ICR mice were induced diabetic by treatment with 
streptozotocin as described in section 2.2. Non-diabetic or diabetic female mice 
were time-mated with male Cyp26almutant mice as described in section 2.1. The 
Cyp26al mouse colony was established from breading pairs of male and female 
heterozygous mice kindly provided by Prof. Hiroshi Hamada. Since Cyp26ar^~ 
mice were non-viable, the colony was maintained by matings between heterozygous 
mice or between heterozygous and wild-type mice. The genotype of mouse was 
verified by PCR as described in section 5.3.2. On day 9.0 of gestation, pregnant 
mice received an intraperitoneal injection of a single dose of 25 mg/kg or 50 mg/kg 
body weight of RA. Embryos were collected at various time points for different 
analyses as described in sections 5.3.3-5.3.5. The yolk sac of embryo was used for 
genotyping as described in section 5.3.2. 
5.3.2. DNA genotyping 
For genotyping, tissues (0.5 mm of the tail tip of adult mouse or the 
yolk sac of embryo) were digested using 150 PCR lysis buffer containing 50 mM 
KCl (BDH), 10 mM Tris in pH 8.0 {Invitrogen), 2 mM MgCb, 0.1 mg/ml gelatin 
iUSB), 0.45% NP40 (Sigma), 0.45% Tween 20 (Sigma) and 0.1 mg/ml proteinase K 
{Roche). Reaction was carried out at 55°C under shaking until all tissues were 
completely digested. The lysate was used directly for PCR reaction without 
purification. 
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Two microlitres of the lysate was added to a PGR reaction mixture 
containing 2 \x\ of lOx PGR buffer, 1.6 of 2.5mM dNTP {Bioneer\ 1.5 |LI1 of 
20mM MgCb {Bioneer), 0.5 \i\ of each primers, 1 |LI1 of 5U/|il Taq polymerase 
(Bioneer) and 5.4 autoclaved water to make up a final volume of 15 |j.l. 
Primers used are as folio wings: 
Primer 1: 5，- GGTAAC GTG GGCAGTAAC CTG -3’ 
Primer 2: 5'- TCC ATG AGC CGA GTT CTG TAG -3' 
Primer 3: 5'- TCC GTT CAG TCA GTC TCA TAG -3’ 
Thirty cycles of PGR reaction were performed in a thermal cycler 
{Applied Biosystem PCR 9600) with denaturing temperature at 95°C for 2 min, 
annealing temperature at 58°C for 30 sec and extension at 72°C for 30 sec. The 
reaction was ended with final extension at 72®C for 8 min. PCR products were 
detected in 3% agarose gel with ethidium bromide using 12 of the PCR aliquot. 
The size of the PCR product was determined by 50 kb DNA ladder {Fementas). 
Cyp26a严 and Cyp26al+ embryos got single PCR product of size 235 bp and 371 
bp respectively, whereas Cyp26a广一 embryos got PCR products of both types. 
5.3.3. Measurement of RA remained in the tail bud after RA treatment 
To compare the RA catabolic activity in the tail bud region of embryos 
in different groups, embryos were dissected out in LI 5 medium at 3 hr after RA 
treatment and the tail bud (as defined in section 3.3.4.2) of embryos at 20-22 
somite-stage was collected. RA level in the tail bud was measured using the RA 
responsive cell line as described in section 3.3.5. 
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5.3.4. Analysis of extent of caudal regression 
Embryos were dissected out at day 13 of gestation. Tail length (TL), 
defined as the length of the caudal region from the posterior limit of the hindlimb 
bud to the end of the tail, and crump-rump length (CRL), defined as the length from 
the top of the head to the bottom of the buttock, were measured with an eyepiece 
graticule on a stereomicroscope (Fig. 5.1). The extent of caudal regression was 
measured in terms of the ratio of tail length to crump-rump length (TL/CRL). 
5.3.5. Real-time quantitative RT-PCR 
Embryos were dissected out at day 9.0 of gestation. The tail bud (as 
defined in section 3.3.4.2) of embryos at 17-19 somite-stage was excised and 
individually stored in RNA/^z/er as described in section 2.5.1. The yolk sac of the 
embryo was used for genotyping as described in section 5.3.2. After genotyping, tail 
bud tissues of embryos of the same genotype were pooled. To compare Cyp26al 
expression in Cyp26al染 and Cyp26al+" embryos of non-diabetic and diabetic 
groups, mRNA levels were measured by real-time quantitative PGR. RNA was 
extracted followed the method in section 2.5.2. Reverse transcription and real-time 
quantitative PCR were conducted as described in sections 2.5.3 and 2.5.4 
respectively, p-actin was used as the internal control for normalization of PCR 
products. To quantify the amount of Cyp26al and P-actin’ cDNA standards were 
co-amplified in each PCR. The standards were prepared as described in section 2.5.5. 
The sequences of primers for amplification of partial sequence of Cyp26al and 
P-actin, and the size of PCR products were as described in section 4.3.2. 
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5.3.6. Statistical analysis 
The expression level of Cyp26al, the amount of RA remaining in the 
tail bud region and the TL/CRL ratio among embryos of the 4 groups (Cyp26al^^~ 
and Cyp26a广z+ embryos in diabetic or non-diabetic pregnancies) were compared by 
one-way ANOVA followed by Bonferroni test. The difference between Cyp26a广-
and Cyp26al+" embryos in diabetic and non-diabetic groups was compared by 
one-way ANOVA followed by Contrast test. All statistical analyses were carried out 
using SPSS software {SPSS)^ with statistical significance level set at p < 0.05. 
Variance of the data sets was determined by Levene's test. 
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5.4. RESULTS 
5.4.1. Comparsion of pregnancy outcome of mating with ICR or 
Cyp26al+— males 
The pregnancy outcome of ICR females mated with ICR or Cyp26al+" 
males was summarized in Table 5.1. The pregnancy rate of ICR females mated with 
Cyp26al+" males was about 10% lower than that with ICR males in both 
non-diabetic (78.9% against 89.5%) and diabetic (62.9% against 73.7%) groups. As 
for the resorption rate (resorption of whole litter), there was not much difference 
between matings with the two types of males. No resorption was found in the 
non-diabetic group and about 7-9% resorption was found in the diabetic group. 
These results showed that mating of ICR females with Cyp26a广"males only 
affected the pregnancy rate but not the viability of pregnancy. 
Table 5.1 Pregnancy outcome of mating between diabetic or non-diabetic 
ICR females with ICR or Cyp26af" males. 
Paternal strain ICR Cyp26a广-S 
Maternal status ND SD ND SD 
No. of mated mice 67 57 57 54 
No. of pregnant mice 60 (89.5%) 42 (73.7%) 45 (78.9%) 34 (62.9%) 
No. of resorbed litters 0 3(7.1%) 0 3 (8.88%) 
5.4.2. Expression levels of Cyp26al determined by real-time 
quantitative RT-PCR 
The expression level of Cyp26a 1 in the tail bud region of embryos in 
different groups was summarized in Table 5.2 and presented in Graph 5.1. Results 
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showed that the expression level of Cyp26al in the tail bud region of Cyp26al 
heterozygous embryos was significantly lower than that of their wild-type 
littermates in both non-diabetic {p < 0.001，ND+Z+ vs. ND+z—) and diabetic groups {p 
=0.001，SD+z+vs. SD"-). Moreover, when comparing the expression level between 
non-diabetic and diabetic groups, both Cyp26a广and Cyp26al來 embryos in 
diabetic pregnancy showed a significantly lower level of Cyp26al expression in the 
tail bud region in comparison to that in non-diabetic pregnancy (p < 0.001, vs. 
SD+杆；p < 0.006, ND+— vs. SD+"). When both maternal and genetic factors were 
considered, the expression level of Cyp26al was the lowest in the tail bud region of 
Cyp26al+'- embryos in diabetic pregnancy, but highest in that of Cyp26a严 
embryos in non-diabetic pregnancy. 
Table 5.2 Relative expression levels of Cyp26al in the tail bud region of 
embryos in different groups at day 9.0 of gestation. 
Maternal status ND SD 
Genotype of Cyp26al , 
mutant embryos 
No. of litters 5 5 5 5 
No. of embryos 22 17 17 18 
Relative expression 0.125 士 0.005 0.097 士 0.002 0.093 ± 0.006 0.072 士 0.003 levels of Cyp26al 土 SE 
5.4.3. Determination of RA catabolic activity 
To determine whether differences in expression levels of Cyp26al 
would affect RA catabolic activity, the relative amount of RA remained in the tail 
bud at 3 hr after maternal treatment with RA was compared among embryos with 
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different gene dosages of Cyp26al under different maternal status (diabetic or 
non-diabetic). Results were summarized in Table 5.3 and presented in Graph 5.2. 
Statistical analyses were summarized in Tables 5.4 and 5.5. Results showed that in 
comparing embryos with different gene dosages of Cyp26al, the relative amount of 
RA remained in the tail bud (assessed in terms of RA released from the tail bud into 
the culture medium) of Cyp26al heterozygous embryos after maternal treatment 
with 25 mg/kg or 50 mg/kg of RA was significantly higher than that of their 
wild-type littermates in both non-diabetic {p < 0.001, vs. ND+z—) and diabetic 
pregnancies {p < 0 . 0 0 1， v s . SD+Z""). 
Table 5.3 Relative amount of RA released from the tail bud region of 
embryos in different groups at 3 hr after maternal treatment with 
25 mg/kg or 50 mg/kg of RA. 
25 mg/kg 
Maternal status ND SD 
Genotype of Cyp26al 
mutant embryos 
No. of litters 7 7 8 8 
No. of embryos 27 23 28 22 
RA concentrations 0.12 士 0.06 0.32 士 0.11 0.30 ±0.16 0.76 士 0.23 (nM) 土 SE 
50 mg/kg 
Maternal status ND SD 
Genotype of Cyp26al 
mutant embryos 
No. of litters 8 8 9 9 
No. of embryos 30 35 34 30 
RA concentrations 
2.60 土 0.17 5.14 士 1.18 5.01 士 0.97 8.39 土 1.56 
(nM) 土 SE 
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Table 5.4 Statistical analysis of relative amount of RA released from the tail 
bud of embryos in different groups using one-way ANOVA followed 
by Bonferroni test. 
p value in comparing relative RA levels 
ND^ ND^ f ^ Dosage of RA 
vs. vs. vs. vs. 
ND+— SD+'+ SD+— SD+" 
25 mg/kg <0.001* <0.001* <0.001* <0.001* 
50 mg/kg <0.001* <0.001* <0.001* <0.001* 
* Statistically significant 
In comparing maternal status, the diabetic group had a significantly 
higher level of RA remained in the tail bud region than that of the non-diabetic 
group in both Cyp26af'~ (p < 0.001, ND""^ " VS. SD+—) and Cyp26a严 embryos (p < 
0.001, ND+Z+ vs. SD+Z+) after maternal treatment with 25 mg/kg or 50 mg/kg of RA. 
Furthermore, the difference in relative amount of RA remained in the 
tail bud region between Cyp26af'~ and Cyp26a严 embryos in non-diabetic and 
diabetic pregnancies was compared using one-way ANOVA followed by Contrast 
test (Table 5.5). Results showed that the difference between Cyp26al heterozygous 
embryos and their wild-type littermates in diabetic pregnancy was much larger than 
that in non-diabetic pregnancy, with a statistically significant difference of/? < 0.001 
for RA dosage at 25 mg/kg and p = 0.04 for RA dosage at 50 mg/kg. 
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Table 5.5 Statistical analysis of differences in the relative amount of RA 
released from the tail bud region between embryos of different 
genotypes in non-diabetic and diabetic groups using one-way 
ANOVA followed by Contrast test. 
p value in comparing RA levels of 
difference between SD+'+ & SD"— Dosage ofRA vs. 
difference between ND"+ & ND+— 
25 mg/kg <0.001* 
50 mg/kg 0.040* 
* Statistically significant 
Moreover, comparison was conducted to determine the effect of dosage 
of RA with results summarized in Table 5.6. It was found that doubling the dosage 
ofRA from 25 mg/kg to 50 mg/kg resulted in at least 10-fold increase in the relative 
amount of RA remained in the tail bud. The fold of difference appeared to be related 
with the expression level of Cyp26al. ND+杆 embryos with the highest Cyp26al 
expression levels (Graph 5.1) showed the largest difference (about 22-fold), whereas 
embryos with the lowest Cyp26al expression levels (Graph 5.1) showed the 
smallest difference (about 11-fold). 
Table 5.6 Fold of differences in relative amount of RA remained in the tail 
bud region between embryos maternally treated with 25 mg/kg and 
50 mg/kg ofRA. 
Maternal status ND SD 
Genotype of Cyp26al , , 
mutant embryos 
Fold of differences in 21.70 16.05 16.82 11.04 relative amount of RA 
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5.4.4. Extent of caudal regression 
To determine if differences in RA catabolic activity found in the tail 
bud of embryos in different groups would result in differences in caudal 
development, the ratio of TL/CRL of embryos was used as a parameter to compare 
the extent of caudal regression (Fig. 5.2). The result of TL/CRL ratio in different 
groups was summarized in Table 5.7, and presented in Graph 5.3 and Figure 5.2. 
Statistical analyses were summarized in Tables 5.8 and 5.9. Results showed that at 
the dose of 25 mg/kg of RA, concomitant with reduced Cyp26al expression levels 
(results from section 5.4.2) and reduced RA catabolic activity (results from section 
5.4.3), Cyp26al heterozygous embryos exhibited more severe caudal regression, as 
demonstrated by a significantly smaller TL/CRL ratio, in comparison to that of their 
wild-type littermates in both non-diabetic {p < 0.001，ND+Z+ vs. ND+z—) and diabetic 
pregnancies {p < 0.001 SD+z+ vs. SD+—)• 
In comparing maternal status, the diabetic group had a significantly 
smaller TL/CRL ratio than that of the non-diabetic group in both Cyp26af'~ 
embryos (p < 0.001, ND+z—vs. SD+—) and Cyp26aQmhryos (p < 0.001，ND+什 vs. 
SD+Z+) maternally treated with 25 mg/kg of RA. The difference in TL/CRL ratio 
between Cyp26al^'~ and Cyp26a严 embryos in non-diabetic and diabetic 
pregnancies was compared using one-way ANOVA followed by contrast test (Table 
5.9). At the dose of 25 mg/kg of RA, the difference in TL/CRL ratio between 
Cyp26al heterozygous embryos and their wild-type littermates in diabetic 
pregnancy was much larger than that in non-diabetic pregnancy, with a significant 
difference of/? = 0.033. 
- 9 0 -
Chapter 5: Cyp26al Knockout Mutants 
When the dose of RA was increased to 50 mg/kg, despite the fact that 
there were significant differences in RA levels in the tail bud region of embryos in 
different groups as reported in section 5.4.3，no significant differences in TL/CRL 
ratio could be found among embryos of the 4 groups at day 13 of gestation because 
all of them exhibited complete caudal regression with no tail. 
Tables 5.7 TL/CRL ratio of embryos at day 13 of gestation in different groups 
after maternal treatment with 25 mg/kg or 50 mg/kg RA on day 9.0 
of gestation. 
25 mg/kg 
Maternal status ND SD 
Genotype of Cyp26al +Z+ +Z +Z+ 
mutant embryos 
No. of litters 10 10 10 10 
No. of embryos 58 62 41 41 
TL/CRL ratio 士 SE 0.408 士 0.007 0.335 土 0.007 0.336 ± 0.009 0.228 士 0.010 
50 mg/kg 
Maternal status ND SD 
Genotype of Cyp26al , , , +/+ + / - +/+ + / -mutant embryos 
No. of litters 5 5 5 5 
No. of embryos 26 20 21 17 
TL/CRL ratio 士 SE 0.068 ± 0.007 0.062 土 0.006 0.053 ± 0.006 0.042 士 0.004 
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Table 5.8 Statistical analysis of the TL/CRL ratio of embryos in different groups 
using one-way ANOVA followed by Bonferroni test. 
p value in comparing TL/CRL ratio 
ND^ ND^ ^ ND^ Dosage of RA 
vs. vs. vs. vs. 
ND+" SD+" SD+" 
25 mg/kg <0.001* <0.001* <0.001* <0.001* 
50 mg/kg 0.667 0.330 0.667 0.097 
* Statistically significant 
Table 5.9 Statistical analysis of differences in the TL/CRL ratio between 
embryos of different genotypes in non-diabetic and diabetic groups 
using one-way ANOVA followed by Contrast test. 
p value in comparing TL/CRL ratio of 
difference between SD+仔 & SD"一 Dosage of RA vs. 
difference between ND+件 & ND+— 
25 mg/kg 0.033* 
50 mg/kg 0.586 
* Statistically significant 
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5.5. DISCUSSION 
The aim of this chapter was to investigate whether there were any 
relationships among maternal diabetes, Cyp26a 1 expression levels and RA catabolic 
activity in the tail bud region of embryos, and whether these factors would affect the 
embryo's susceptibility to caudal regression. Results of this chapter clearly showed 
that relationships existed among these three factors. Heterozygous embryos with 
haploinsufficiency of Cyp26a 1 in diabetic pregnancy was most susceptible to 
RA-induced caudal regression. The lower the Cyp26a 1 expression level, the higher 
the RA level remained in the tail bud region of the embryo at 3 hr after RA treatment, 
and the shorter the TL/CRL ratio at day 13 of gestation. 
Upon administration of 50 mg/kg of RA, although a differential 
difference in RA levels among embryos was observed in the tail bud region in 
different groups (Graph 5.2)，no significant difference could be found in TL/CRL 
ratio as all embryos showed severe caudal regression (section 5.4.4, Graph 5.3). 
When the dose of RA was reduced to 25 mg/kg, different degree of severity of 
caudal regression could be observed in embryos of different groups, such that the 
extent of caudal regression was directly related with the RA level in the tail bud 
region. The higher the RA level, the smaller the TL/CRL ratio, i.e. the greater the 
extent of caudal regression. This result suggests that there is a threshold of RA level 
in the tail bud region for developing complete caudal regression. Once the RA level 
exceeds the threshold value, complete caudal regression will be resulted. On the 
other hand, if low doses of RA are applied, different extent of caudal regression can 
be observed, with the degree of severity being proportional to the RA level in the tail 
bud. 
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Furthermore, regarding the RA catabolic activity, as indicated by the 
amount of RA remained in the tail bud at 3 hr after RA treatment, the difference 
between SD+z+ and SD+— embryos was found to be significantly greater than the 
difference between ND+件 and ND+z— embryos (Table 5.5). Such finding might 
probably be due to differences in the extent of RA-induced up-regulation of 
Cyp26al as found in Chapter 4. As mentioned before, Cyp26al has two RAREs and 
is RA-inducible (Ray et al., 1997; lulianella et al., 1999; Loudig et al., 2000; Loudig 
et al., 2005). Upon exposure to exogenous RA, the expression of Cyp26al was 
up-regulated in the posterior region of the embryo. However, the extent of 
up-regulation of Cyp26al in the diabetic group was significantly less than that in the 
non-diabetic group (Tables 4.2 and 4.4). These results lead to my hypothesis that 
maternal diabetes together with haploinsufficiency of Cyp26al in the heterozygous 
genotype exerted a synergistic effect in reducing the up-regulation of Cyp26al. 
Hence, upon treatment with exogenous RA, there were significant differences in the 
extent of up-regulation of Cyp26al in the 4 groups of embryos, with Cyp26af'~ 
embryos in diabetic pregnancy showing the least up-regulation of Cyp26al and thus 
the lowest RA catabolic activity. This will thereby result in a much larger differences 
in RA levels between Cyp26al heterozygous embryos and their wild-type littermates 
in the diabetic group than that in the non-diabetic group. To prove this hypothesis, 
the level of up-regulation of Cyp26al in Cyp26al+卜 and Cyp26a严 embryos in 
diabetic and non-diabetic pregnancies upon RA induction should be determined. 
Furthermore, as shown in Table 5.6, the fold of difference in RA levels 
between 25 mg/kg and 50 mg/kg of RA was not simply doubled, but at least 10-fold 
higher upon treatment with 50 mg/kg of RA. This can be caused by different 
- 9 4 -
Chapter 5: Cyp26al Knockout Mutants 
mechanisms. For example, this may be due to the rate of diffusion of RA into the 
embryo being much faster than the rate of catabolism under high dose of RA 
treatment, and thus RA accumulates in the tissue. On the other hand, under low dose 
of RA treatment, the rate of catabolism may be similar or even faster than its 
diffusion rate, so a lower RA level is detected. Another mechanism can be related 
with differences in extent of up-regulation of Cyp26al upon exposure to low and 
high doses of RA. However, whatever the mechanism(s) is/are, results of this study 
suggest that RA teratogenicity is not simply a linear relationship with the dose, but 
an exponential relationship may exist. 
Cyp26al null mutants exhibit a number of phenotypes that mimic those 
generated by exposure to excess RA. However, they could be rescued by 
heterozygous disruption of Raldh2 responsible for RA synthesis (Niederreither et al., 
2002). Raldh2 haploinsufficiency prevented the occurrence of spina bifida and 
rescued development of posterior structures. These findings are in agreement with 
my results that the lower the Cyp26al expression level, the higher the level of RA 
remained in the tail bud after RA treatment and the greater the disruption of caudal 
development. Such high concentrations of RA can down-regulate many genes that 
are important for caudal development, such as WntSa and Brachyury in the tail bud 
region, and increase the susceptibility of the embryo to caudal regression. It is 
therefore expected that if the RA level in the embryo of diabetic pregnancy can be 
maintained at a non-teratogenic level, it is possible to reduce the risk of caudal 
regression, or even other types of congenital malformations. 
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6.1. CONCLUSION AND FUTURE PERSPECTIVES 
In our laboratory, we have found that the expression of the RA 
catabolizing enzyme, Cyp26al, was significantly down-regulated in the tail bud 
region of the mouse embryo under maternal diabetes. The aim of this thesis was to 
test our hypothesis that such down-regulation would increase the embryo's 
susceptibility to caudal regression commonly associated with diabetic pregnancy. To 
begin with, in Chapter 3，RA catabolism in the tail bud region of diabetic and 
non-diabetic mice was compared. First, I have established experimental protocols to 
measure RA released from small pieces of embryonic tissues (tail bud) by the highly 
sensitive RA responsive cell line. Then, using an in vitro assay system, I showed that 
CYP26 was the major enzyme responsible for RA catabolism in the tail bud region, 
and the RA catabolic activity was reduced in the tail bud region of embryos of 
diabetic mice. Next, I have used an in vivo approach to demonstrate that 
concomitant with reduced RA catabolic activity, when embryos in diabetic 
pregnancy were exposed in utero to an exogenous dose of RA, the effective 
concentration of RA in the tail bud region was significantly higher than that in 
embryos of non-diabetic pregnancy, which might possibly lead to increased RA 
teratogenicity. 
To follow on, in Chapter 4，I have compared the expression level of the 
three Cyp26 genes, including Cyp26al, Cyp26bl and Cyp26cl, in embryos of 
diabetic and non-diabetic mice. Among them, Cyp26al was the predominant 
subtypes in the tail bud region, with expression levels being at least 10 times higher 
than the other two. Moreover, Cyp26al was the only subtype found to be 
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significantly down-regulated in the tail bud region of embryos under maternal 
diabetes. Upon exposure to exogenous RA, although Cyp26al expression levels 
increased, the extent of up-regulation of Cyp26al was significantly much less in 
embryos of diabetic pregnancy. This result was consistent with the finding in 
Chapter 3 that there was significantly higher levels of RA remained in the tail bud of 
embryos of diabetic mice after maternal RA treatment, reflecting the weaker RA 
catabolic activity. 
Caudal regression was the major phenotype found in Cyp26al 
homozygous knockout mice (Abu-Abed et al., 2001; Sakai et al., 2001). To 
investigate whether down-regulation of Cyp26al in the tail bud of embryos of 
diabetic mice was directly associated with increased risk of caudal regression, in 
Chapter 5, I have studied the relationship of maternal diabetes, Cyp26al expression 
levels and RA catabolism in increasing the susceptibility to RA-induced caudal 
regression. This was achieved by comparing the response of Cyp26al^'' mutant 
embryos, with haploinsufficiency of Cyp26al, with their wild-type littermates to RA 
teratogenicity under diabetic and non-diabetic pregnancies. Results showed that 
heterozygous embryos in diabetic pregnancy had the lowest expression level of 
Cyp26al whereas wild-type embryos in non-diabetic pregnancy had the highest 
level. Concomitant with a difference in the expression level of Cyp26al’ when 
maternally exposed to RA, the tail bud region of Cyp26al+丨-embryos of diabetic 
mice showed the lowest RA catabolic activity (indicated by the highest amount of 
RA remained in the tail bud after RA treatment) and exhibited the most severe 
caudal regression (indicated by the smallest TL/CRL ratio). On the other hand, 
wild-type embryos of non-diabetic mice showed the highest RA catabolic activity 
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and exhibited the least severe caudal regression. Taken together, findings of this 
chapter clearly showed that differences in Cyp26al expression levels affected RA 
catabolism in the tail bud region, resulting in different degree of severity of caudal 
regression. 
Although results of this thesis have provided evidence that significant 
down-regulation of Cyp26al in the embryo is directly involved in increased 
susceptibility to caudal regression in diabetic pregnancy, the underlying mechanism 
of how maternal diabetes affects the expression level of Cyp26al in the embryo is 
still a question. The following hypotheses are drawn up for future investigations. 
Hypothesis 1 
As mentioned in Chapter 1, RA in the embryo is synthesized from 
retinol obtained from maternal circulation. It is well-documented that the plasma 
retinol level of diabetic patients and streptozotocin-induced diabetic rats is 
significantly lower than normal (Wako et al., 1986; Marrtinoli et al., 1993; Tuitoek 
et al., 1996). In a preliminary study to determine the plasma retinol level in pregnant 
and non-pregnant mice under non-diabetic and diabetic status (data not shown), I 
have found that the plasma retinol level was reduced by almost half when mice 
became pregnant, and this difference was further exaggerated in mice with diabetes, 
suggesting that retinol supply from maternal plasma under diabetic pregnancy may 
be insufficient. Besides, the circulatory retinol binding protein responsible for 
uptake of retinol into the embryo is also found decreased under diabetes (Basu et al., 
1989; Tuitoek et al., 1996). Hence, these reductions in maternal plasma retinol and 
- 9 9 -
Chapter 6: Conclusion & Future Perspectives 
retinol binding protein levels in diabetic pregnancy may lead to a decrease in the 
endogenous level of RA in the embryo, thereby causing down-regulation of 
Cyp26al, as expression of Cyp26al has been shown to be regulated by RA/retinol 
levels (Yamamoto et al., 2000; Wang et al., 2002). To investigate this hypothesis, the 
concentration of retinol and its derivatives, including dX\-trans, \2)-cis, 9-cis RA, in 
the embryo under diabetic and non-diabetic pregnancies should be determined. The 
expression of different retinoid binding proteins, such as cellular retinol binding 
proteins and cellular retinoic acid binding proteins, which regulate the availability of 
retinol and RA to the embryo, should also be examined. 
Hypothesis 2 
Our laboratory has previously shown that embryos made transiently 
hyperglycemic by repeated glucose injections exhibited an increased incidence of 
caudal regression upon treatment with RA (Leung et al., 2004). On the other hand, 
normalization of blood glucose level in diabetic mice by phlorizin (a drug that 
prevents re-absorption of glucose in the renal tubule) could reduce the susceptibility 
of the embryo to RA-induced caudal regression (Leung et al., 2004). These results 
suggest that hyperglycemia and diabetes may act via a similar signaling pathway to 
affect the embryo and the candidate molecule is probably glucose. Hence, it is 
hypothesized that glucose may alter the expression of some RA-related genes that in 
turn increases RA teratogenicity. However, this hypothesis will lead to the question 
of how glucose affects gene expression. 
As mentioned in Chapter 1, oxidative stress generated under diabetes 
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mellitus is the cause of many types of congenital malformations (Eriksson et al., 
1990). Anti-oxidation treatment has been shown to rescue pregnancies from these 
malformations (Eriksson and Siman, 1996; Siman and Eriksson, 1997). Glucose, 
which causes lipid per-oxidation and generation of different aldehydes under 
diabetes, has been reported to inhibit RA synthesis in embryonic tissues (Chen et al., 
1998). It is therefore hypothesized that elevation of glucose level under diabetes 
may generate different aldehydes, which inhibit RA synthesis and thus affect the RA 
signaling pathway. To test this hypothesis, first, embryos can be cultured in glucose-
or aldehyde-supplemented medium to determine if there are any changes in the 
expression level of RA synthesizing genes (Raldhs) and the endogenous RA 
concentration, and induction of malformations. Further experiments can be done to 
test if any of these changes and malformations can be abolished/ameliorated by 
co-treatment with aldehyde inhibitors. 
Diabetes mellitus is one of the most common diseases and the global 
prevalence of diabetes is increasing in an alarming rate (King et al., 1998). Moreover, 
there is a growing trend towards earlier onset of diabetes. Hence, it is expected that 
an increasing number of people will be diabetic during child-bearing ages, and so 
the problem of diabetic embryopathy is going to exacerbate. It is therefore of utmost 
importance to understand the underlying mechanism of increased susceptibility to 
congenital malformations associated with diabetic pregnancy. Results of this thesis 
have provided new insights that maternal diabetes can increase the risk of congenital 
malformation via alteration of RA-related mechanisms. It is hoped that this finding 
may pave the way for deriving preventive measures to reduce the risk of adverse 
pregnancy outcome associated with diabetic pregnancy. 
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Fig. 3.1 Signal intensity of X-gal stained RA responsive cells. 
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Image of the X-gal stained RA responsive cells on the 96-well plate that had been 
incubated with serially diluted RA standard solutions for 25 hr. 
Fig. 3.2 Experimental set-up of the in vitro assay. 
Day 9 
H H ^ ^ ^ ^ ^ H On day 9.0 of gestation, the tail bud of 
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contain ing: medium containing 50 nM of RA and 
• • Rp^ eznyme cofactor-reducing agent. 
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V I 4. 
• I n c u b a t e i n d a r k During incubation, RA in the medium was 
I /竹。广 o h r \ degraded by the RA catabolizing enzyme • (o /^UTorznr ; the tail bud lysate. 
Determinat ion of RA 5. 
c o n c e n t r a t i o n b y RA remaining in the medium was 
„ _ • , , , . measured by using the highly sensitive 
RA respons ive cel l l ine RA responsive cell line. 
Fig. 3.3 Toxicity of the in vitro assay medium containing diluted or undiluted 
NADPH (1.6 mg/ml) and DTT (0.3 mg/ml) on the RA responsive cell 
line after cultured for 25 hr. 
A Image of the cell line after cultured in medium containing undiluted 
NADPH-DTT. All cells were killed under high concentrations of 
NADPH-DTT. 
B Higher magnification of the cell image in A, showing the dead cells had 
shrunken and detached from the culture plate. 
C Image of the cell line after cultured in medium containing 3-fold diluted 
NADPH-DTT. The cell density was low with many dead cells detached from 
the culture plate and floated on top of the live cells. 
D Higher magnification of the cell image in C, showing many dead cells (in 
round shape) floating on top of some live cells (arrowhead). 
E Image of the cell line after cultured in medium containing 9-fold diluted 
NADPH-DTT. The cell density had significantly increased in comparison to 
cells cultured in 3-fold diluted medium as in C. 
F Higher magnification of the cell image in E. The RA responsive cells were 
attached on the plate in a normal morphology. Only a few dead cells (arrow) 
were found. 
Scale bar: A, C, E 200 
B, D, F 66.7 [im 
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Fig. 3.3 Toxicity of the in vitro assay medium containing diluted or undiluted 
NADPH (1.6 mg/ml) and DTT (0.3 mg/ml) on the RA responsive cell 
line after cultured for 25 hr. 
G Image of the cell line after cultured in medium containing 27-fold diluted 
NADPH-DTT. The cells had grown to confluence. 
H Higher magnification of the cell image in G. The boundary of the cells could 
not be clearly identified as the cells were tightly packed. 
I Sensitivity of the cell line to 50 nM of RA (concentration of RA actually 
detected) when cultured in medium containing serially diluted NADPH-DTT. 
Maximum sensitivity was achieved at a dilution factor of 27-fold or above. 
Scale bar: G 200 i^m 
H 66.7 |Lim 
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Fig. 3.4 Experimental set-up of the in vivo assay. 
Day 9 1 a On day 9.0 of gestation, diabetic and non-
diabetic pregnant mice were intraperitoneally 
injected with RA at a dose of 50 mg/kg body 
weight. 
Injection of 50 mg/kg RA 
, 拿 < < _ 寒 _ _ 1 2 3 4 5 6 7 8 hr 2 . 
/ The tail bud of embryos was collected at 1-
“ hr interval until the 8出 hr. 
• Tail Bud 
—、门 3. 
_ _ Individual tail bud was put into DMEM 




• Incubate in dark ^ I (37�C for 25 hr) RA released into the medium was 
秦 measured by using the highly sensitive RA 
• responsive cell line. 
Determination of RA 
concentration by 
RA responsive cell line 
Fig. 5.1 Illustration of how the tail length and crump-rump length were 
measured. 
A Crump-rump length (CRL) was the maximum length of the body from the top 
of the head to the bottom of the buttock as indicated by the blue double arrows. 
The original position of the hindlimb bud was outlined with green dotted lines. 
The hindlimb bud was removed for showing the entire caudal region of the 
embryo. 
B Tail length (TL) was defined as the length of the caudal region from the 
posterior limit of the hindlimb bud (original position was outlined with green 
dotted lines) to the end of the tail as indicated by the black double arrows. The 
tail region was straightened during measurement. 
- J a: o J 國國 
Fig. 5.2 Embryos of different groups examined at day 13 of gestation with 
different extent of caudal regression after maternal treatment with 
25 mg/kg of RA on day 9.0 of gestation. 
A Cyp26a严 embryos of non-diabetic mice (ND+Z+) with the strongest 
expression level of Cyp26al showed the less severity of RA-induced caudal 
regression. 
B Cyp26al"- embryos of non-diabetic mice (ND+z—) with halpoinsufficiency 
of Cyp26al showed a shorter tail length in comparison to Cyp26a严 
embryos in non-diabetic pregnancy as indicated in A. 
C Cyp26a严 embryos of diabetic mice (SD+Z+) showed a shorter tail length in 
comparison to embryos of the same genotype in non-diabetic pregnancy as 
indicated in A. 
D Cyp26al+" embryos of diabetic mice (SD+z_) with the lowest expression 
level of Cyp26al showed the most severe RA-induced caudal regression. 
Scale bar: A-D 0.5 mm 

Graphs 
Graph 3.1 Standard curves showing signal intensity of RA responsive cells 
that had been incubated with serially diluted RA standard 
solutions for different length of time. 
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Graph 3.2 Linear regression line as a standard curve for calculating the 
concentration of RA in the sample. 
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The linear regression line was prepared by incubating the RA responsive cells on the 96-
well plate with different concentrations RA solutions (lO ?’ 10-8，10-83, lO'^ , 10-93 and 
10-10 M) for 25 hr. 
Graph 3.3 Standard curves showing response of RA responsive cells to 
serially diluted RA standard solutions in normal or 100-fold 
higher concentration of DMSO. 
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* The signal intensity (optical density, OD, at wavelength of 650 nm) was expressed 
as a percentage relative to the maximum intensity (100%) at 10"^  M of RA in 
normal DMSO concentration. 
n = 3 in each group 
Graph 3.4 Comparison of P-gal Assay Kit and P-gal staining assay in 
detecting P-galactosidase in the RA responsive cells in response 
to serially diluted RA standard solutions. 
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Graph 3.5 Comparison of in vitro RA catabolic activity of lysed and intact 
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Graph 3.6 Effect of enzyme cofactor and inhibitor on in vitro RA catabolic 
activity of tail bud tissue. 
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Data were analyzed by Independent sample t test. 
• p < 0.001 vs. Blank 
t p < 0.05 vs. Blank 
< 0.001 vs. Tail bud lysate added with NADPH-DTT 
Graph 3.7 Comparison of in vitro RA catabolic activity of tail bud tissue of non-
diabetic and diabetic groups. 
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Data were analyzed by Independent sample t test. 
• p < 0.001 vs. ND tail bud lysate with co-factor and reducing agent 
t p < 0.001 vs. Blank 
Graph 3.8 Amount of RA released from the tail bud region of embryo into 
the medium at different time points after maternal treatment with 
50 mg/kg ofRAfor3hr. 
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Graph 3.9 Amount of RA released from the tail bud region of embryos in non-
diabetic and diabetic mice measured at different time points after 
maternal treatment with 50 mg/kg of RA. 
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Data were analyzed by Independent sample t test. 
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Graph 4.1 Relative expression levels of Cyp26al, Cyp26bl and Cyp26cl in the 
tail bud region of embryos of non-diabetic and diabetic mice at 
day 9.0 of gestation. 
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Graph 4.2 Relative expression levels of Cyp26al in the tail bud region of 
embryos of non-diabetic and diabetic mice at different time points 
after maternal treatment with 50 mg/kg of RA on day 9.0 of gestation. 
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Data were analyzed by Independent sample t test. 
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Graph 5.1 Relative expression levels of Cyp26al in the tail bud region of embryos 
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Data were analyzed by one-way ANOVA followed by Bonferroni test. 
* p< 0.001 vs. ND+/+ 
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Graph 5.2 Relative amount of RA released from the tail bud region of embryos 
in different groups at 3 hr after maternal treatment with 25 mg/kg 
or 50 mg/kg of RA on day 9.0 of gestation. 
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^p < 0.001 vs. ND+— 
Graph 5.3 TL/CRL ratio of embryos in different groups measured at day 13 of 
gestation after maternal treatment with 25 mg/kg or 50 mg/kg of RA 
on day 9.0 of gestation. 
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Cyp26al+'+ embryos of non-diabetic mothers 
ND+—: Cyp26al^'~ embryos of non-diabetic mothers 
SD+Z+: Cyp26al+K embryos of diabetic mothers 
SD+—: Cyp26at'~ embryos of diabetic mothers 
Data were analyzed by one-way ANOVA followed by Bonferroni test. 
* p < 0.001 vs. ND+/+ 
#/7< 0.001 vs. SD+/+ 
印 < 0.001 vs. ND+" 
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